(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization International Bureau

(51) International Patent Classification7:



(43) International Publication Date 2 August 2001 (02.08.2001) (10) International Publication Number
WO 01/54719 A2

- 31/70, 47/00, C12N 15/49, 15/62, C07K 14/16, 19/00
- (21) International Application Number: PCT/EP01/00944
- (22) International Filing Date: 29 January 2001 (29.01.2001)
- (25) Filing Language:

English

- (26) Publication Language: English
- (30) Priority Data: 0002200.4 31 January 2000 (31.01.2000) GB 0009356.9 14 April 2000 (14.04.2000) GB 0013806.5 6 June 2000 (05.06.2000) GP PCT/EPD0005998 22 June 2000 (28.06.2000) GP
- (71) Applicant (for all designated States except US): SMITHKLINE BEECHAM BIOLOGICALS S.A. [BE/BE]; Rue de l'Institut 89, B-1330 Rixensart (BE).
- (72) Inventor; and
- (75) Inventor/Applicant (for US only): VOSS, Gerald [DE/BE]; SmithKline Beeacham Biologicals S.A., Rue de l'Institut 89, B-1330 Rixensart (BE).

- A61K 39/21, (74) Agent: PRIVETT, Kathryn, Louise; Corporate Intellectual Property, SmithKline Beecham, Two New Horizons Court. Brentford, Middlesex TW8 9EP (GB),
 - (81) Designated States InationalJ: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, PB, 2C, AC, HC, NC, CC, UC, CD, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SS, SG, SI, SK, SL, TI, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZA
 - (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DE, BS, FI, FR, GB, GR, EE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, Cl, CM, GA, GN, GW, ML, MR, NE, SN, TD, TO).

Published:

 without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: NOVEL USE

NOVEL USE

DESCRIPTION

The present invention relates to novel uses of HIV proteins in medicine and vaccine compositions containing such HIV proteins. In particular, the invention relates to the use of HIV Tat and HIV gp120 proteins in combination. Furthermore, the invention relates to the use of HIV Nef and HIV gp120 proteins in combination.

HIV-1 is the primary cause of the acquired immune deficiency syndrome (AIDS) which is regarded as one of the world's major health problems. Although extensive research throughout the world has been conducted to produce a vaccine, such efforts thus far have not been successful.

The HIV envelope glycoprotein gp120 is the viral protein that is used for attachment to the host cell. This attachment is mediated by the binding to two surface molecules of helper T cells and macrophages, known as CD4 and one of the two chemokine receptors CCR-4 or CXCR-5. The gp120 protein is first expressed as a larger precursor molecule (gp160), which is then cleaved post-translationally to yield gp120 and gp41. The gp120 protein is retained on the surface of the virion by linkage to the gp41 molecule, which is inserted into the viral membrane.

The gp120 protein is the principal target of neutralizing antibodies, but unfortunately the most immunogenic regions of the proteins (V3 loop) are also the most variable parts of the protein. Therefore, the use of gp120 (or its precursor gp160) as a vaccine antigen to elicit neutralizing antibodies is thought to be of limited use for a broadly protective vaccine. The gp120 protein does also contain epitopes that are recognized by cytotoxic T lymphocytes (CTL). These effector cells are able to eliminate virus-infected cells, and therefore constitute a second major antiviral immune mechanism. In contrast to the target regions of neutralizing antibodies some CTL epitopes appear to be relatively conserved among different HIV strains. For this reason gp120 and gp160 are considered to be useful antigenic components in vaccines that aim at eliciting cell-mediated immune responses (particularly CTL).

1

Non-envelope proteins of HIV-1 have been described and include for example internal structural proteins such as the products of the gag and pol genes and, other non-structural proteins such as Rev, Nef, Vif and Tat (Greene et al., New England J. Med, 324, 5, 308 et seq (1991) and Bryant et al. (Ed. Pizzo), Pediatr. Infect. Dis. J., 11, 5, 390 et seq (1992).

HIV Tat and Nef proteins are early proteins, that is, they are expressed early in infection and in the absence of structural protein.

In a conference presentation (C. David Pauza, Immunization with Tat toxoid attenuates SHIV89.6PD infection in rhesus macaques, 12th Cent Gardes meeting, Marnes-La-Coquette, 26.10.1999), experiments were described in which rhesus macaques were immunised with Tat toxoid alone or in combination with an envelope glycoprotein gp160 vaccine combination (one dose recombinant vaccinia virus and one dose recombinant protein). However, the results observed showed that the presence of the envelope glycoprotein gave no advantage over experiments performed with Tat alone.

However, we have found that a Tat- and/or Nef-containing immunogen (especially a Nef-Tat fusion protein) acts synergistically with gp120 in protecting rhesus monkeys from a pathogenic challenge with chimeric human-simian immunodeficiency virus (SHIV). To date the SHIV infection of rhesus macaques is considered to be the most relevant animal model for human AIDS. Therefore, we have used this preclinical model to evaluate the protective efficacy of vaccines containing a gp120 antigen and a Nef- and Tat-containing antigen either alone or in combination. Analysis of two markers of viral infection and pathogenicity, the percentage of CD4-positive cells in the peripheral blood and the concentration of free SHIV RNA genomes in the plasma of the monkeys, indicated that the two antigens acted in synergy. Immunization with either gp120 or NefTat + SIV Nef alone did not result in any difference compared to immunization with an adjuvant alone. In contrast, the administration of the combination of gp120 and NefTat + SIV Nef, antigens resulted in a marked improvement of the two above-mentioned parameters in all animals of those particular experimental group.

Thus, according to the present invention there is provided a new use of HIV Tat and/or Nef protein together with HIV gp120 in the manufacture of a vaccine for the prophylactic or therapeutic immunisation of humans against HIV.

As described above, the NefTat protein, the SIV Nef protein and gp120 protein together give an enhanced response over that which is observed when either NefTat + SIV Nef, or gp120 are used alone. This enhanced response, or synergy can be seen in a decrease in viral load as a result of vaccination with these combined proteins. Alternatively, or additionally the enhanced response manifests itself by a maintenance of CD4+ levels over those levels found in the absence of vaccination with HIV NefTat, SIV Nef and HIV gp120. The synergistic effect is attributed to the combination of gp120 and Tat, or gp120 and Nef, or gp120 and both Nef and Tat.

The addition of other HIV proteins may further enhance the synergistic effect, which was observed between gp120 and Tat and/or Nef. These other proteins may also act synergistically with individual components of the gp120, Tat and/or Nef-containing vaccine, not requiring the presence of the full original antigen combination. The additional proteins may be regulatory proteins of HIV such as Rev, Vif, Vpu, and Vpr. They may also be structural proteins derived from the HIV gag or pol genes.

The HIV gag gene encodes a precursor protein p55, which can assemble spontaneously into immature virus-like particles (VLPs). The precursor is then proteolytically cleaved into the major structural proteins p24 (capsid) and p18 (matrix), and into several smaller proteins. Both the precursor protein p55 and its major derivatives p24 and p18 may be considered as appropriate vaccine antigens which may further enhance the synergistic effect observed between gp120 and Tat and/or Nef. The precursor p55 and the capsid protein p24 may be used as VLPs or as monomeric proteins.

The HIV Tat protein in the vaccine of the present invention may, optionally be linked to an HIV Nef protein, for example as a fusion protein.

The HIV Tat protein, the HIV Nef protein or the NefTat fusion protein in the present invention may have a C termir al Histidine tail which preferably comprises between 5-10 Histidine residues. The presence of an histidine (or 'His') tail aids purification.

In a preferred embodiment the proteins are expressed with a Histidine tail comprising between 5 to 10 and preferably six Histidine residues. These are advantageous in aiding purification. Separate expression, in yeast (Saccharomyces cerevisiae), of Nef (Macreadie I.G. et al., 1993, Yeast 9 (6) 565-573) and Tat (Braddock M et al., 1989, Cell 58 (2) 269-79) has been reported. Nef protein and the Gag proteins p55 and p18 are myristilated. The expression of Nef and Tat separately in a Pichia expression system (Nef-His and Tat-His constructs), and the expression of a fusion construct Nef-Tat-His have been described previously in WO99/16884.

The DNA and amino acid sequences of representative Nef-His (Seq. ID. No.s 8 and 9), Tat-His (Seq. ID. No.s 10 and 11) and of Nef-Tat-His fusion proteins (Seq. ID. No.s 12 and 13) are set forth in Figure 1.

The HIV proteins of the present invention may be used in their native conformation, or more preferably, may be modified for vaccine use. These modifications may either be required for technical reasons relating to the method of purification, or they may be used to biologically inactivate one or several functional properties of the Tat or Nef protein. Thus the invention encompasses derivatives of HIV proteins which may be, for example mutated proteins. The term 'mutated' is used herein to mean a molecule which has undergone deletion, addition or substitution of one or more amino acids using well known techniques for site directed mutagenesis or any other conventional method.

For example, a mutant Tat protein may be mutated so that it is biologically inactive whilst still maintaining its immunogenic epitopes. One possible mutated tat gene, constructed by D.Clements (Tulane University), (originating from BH10 molecular clone) bears mutations in the active site region (Lys41-Ala)and in RGD motif (Arg78-Lys and Asp80-Glu) (Virology 235: 48-64, 1997).

A mutated Tat is illustrated in Figure 1 (Seq. ID. No.s 22 and 23) as is a Nef-Tat Mutant-His (Seo. ID. No.s 24 and 25).

The HIV Tat or Nef proteins in the vaccine of the present invention may be modified by chemical methods during the purification process to render the proteins stable and monomeric. One method to prevent oxidative aggregation of a protein such as Tat or Nef is the use of chemical modifications of the protein's thiol groups. In a first step the disulphide bridges are reduced by treatment with a reducing agent such as DTT, beta-mercaptoethanol, or gluthatione. In a second step the resulting thiols are blocked by reaction with an alkylating agent (for example, the protein can be carboxyamidated/carbamidomethylated using iodoacetamide). Such chemical modification does not modify functional properties of Tat or Nef as assessed by cell binding assays and inhibition of lymphoproliferation of human peripheral blood mononuclear cells.

The HIV Tat protein and HIV gp120 proteins can be purified by the methods outlined in the attached examples.

The vaccine of the present invention will contain an immunoprotective or immunotherapeutic quantity of the Tat and/or Nef or NefTat and gp120 antigens and may be prepared by conventional techniques.

Vaccine preparation is generally described in New Trends and Developments in Vaccines, edited by Voller et al., University Park Press, Baltimore, Maryland, U.S.A. 1978. Encapsulation within liposomes is described, for example, by Fullerton, U.S. Patent 4,235,877. Conjugation of proteins to macromolecules is disclosed, for example, by Likhite, U.S. Patent 4,372,945 and by Armor et al., U.S. Patent 4,474,757.

The amount of protein in the vaccine dose is selected as an amount which induces an immunoprotective response without significant, adverse side effects in typical vaccinees. Such amount will vary depending upon which specific immunogen is employed. Generally, it is expected that each dose will comprise 1-1000 µg of each

protein, preferably 2-200 µg, most preferably 4-40 µg of Tat or Nef or NefTat and preferably 1-150 µg, most preferably 2-25 µg of gp120. An optimal amount for a particular vaccine can be ascertained by standard studies involving observation of antibody titres and other responses in subjects. One particular example of a vaccine dose will comprise 20 µg of NefTat and 5 or 20 µg of gp120. Following an initial vaccination, subjects may receive a boost in about 4 weeks, and a subsequent second booster immunisation.

The proteins of the present invention are preferably adjuvanted in the vaccine formulation of the invention. Adjuvants are described in general in Vaccine Design – the Subunit and Adjuvant Approach, edited by Powell and Newman, Plenum Press, New York. 1995.

Suitable adjuvants include an aluminium salt such as aluminium hydroxide gel (alum) or aluminium phosphate, but may also be a salt of calcium, iron or zinc, or may be an insoluble suspension of acylated tyrosine, or acylated sugars, cationically or anionically derivatised polysaccharides, or polyphosphazenes.

In the formulation of the invention it is preferred that the adjuvant composition induces a preferential Th1 response. However it will be understood that other responses, including other humoral responses, are not excluded.

An immune response is generated to an antigen through the interaction of the antigen with the cells of the immune system. The resultant immune response may be broadly distinguished into two extreme catagories, being humoral or cell mediated immune responses (traditionally characterised by antibody and cellular effector mechanisms of protection respectively). These categories of response have been termed Th1-type responses (cell-mediated response), and Th2-type immune responses (humoral responses).

Extreme Th1-type immune responses may be characterised by the generation of antigen specific, haplotype restricted cytotoxic T lymphocytes, and natural killer cell responses. In mice Th1-type responses are often characterised by the generation of

antibodies of the IgG2a subtype, whilst in the human these correspond to IgG1 type antibodies. Th2-type immune responses are characterised by the generation of a broad range of immunoglobulin isotypes including in mice IgG1, IgA, and IgM.

It can be considered that the driving force behind the development of these two types of immune responses are cytokines, a number of identified protein messengers which serve to help the cells of the immune system and steer the eventual immune response to either a Th1 or Th2 response. Thus high levels of Th1-type cytokines tend to favour the induction of cell mediated immune responses to the given antigen, whilst high levels of Th2-type cytokines tend to favour the induction of humoral immune responses to the antigen.

It is important to remember that the distinction of Th1 and Th2-type immune responses is not absolute. In reality an individual will support an immune response which is described as being predominantly Th1 or predominantly Th2. However, it is often convenient to consider the families of cytokines in terms of that described in murine CD4 +ve T cell clones by Mosmann and Coffman (Mosmann, T.R. and Coffman, R.L. (1989) TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annual Review of Immunology, 7, p145-173). Traditionally, Th1-type responses are associated with the production of the INF- γ and IL-2 cytokines by T-lymphocytes. Other cytokines often directly associated with the induction of Th1-type immune responses are not produced by T-cells, such as IL-12. In contrast, Th2- type responses are associated with the secretion of IL-4, IL-5, IL-6, IL-10 and tumour necrosis factor- β (TNF- β).

It is known that certain vaccine adjuvants are particularly suited to the stimulation of either Th1 or Th2 - type cytokine responses. Traditionally the best indicators of the Th1:Th2 balance of the immune response after a vaccination or infection includes direct measurement of the production of Th1 or Th2 cytokines by T lymphocytes in vitro after restimulation with antigen, and/or the measurement of the IgG1:IgG2a ratio of antigen specific antibody responses.

7

Thus, a Th1-type adjuvant is one which stimulates isolated T-cell populations to produce high levels of Th1-type cytokines when re-stimulated with antigen in vitro, and induces antigen specific iramunoglobulin responses associated with Th1-type isotype.

Preferred Th1-type immunostimulants which may be formulated to produce adjuvants suitable for use in the present invention include and are not restricted to the following.

Monophosphoryl lipid A, in particular 3-de-O-acylated monophosphoryl lipid A (3D-MPL), is a preferred Th1-type immunostimulant for use in the invention. 3D-MPL is a well known adjuvant manufactured by Ribi Immunochem, Montana. Chemically it is often supplied as a mixture of 3-de-O-acylated monophosphoryl lipid A with either 4, 5, or 6 acylated chains. It can be purified and prepared by the methods taught in GB 2122204B, which reference also discloses the preparation of diphosphoryl lipid A, and 3-O-deacylated variants thereof. Other purified and synthetic lipopolysaccharides have been described (US 6,005,099 and EP 0 729 473 B1; Hilgers et al., 1986, Int.Arch.Allergy.Immunol., 79(4):392-6; Hilgers et al., 1987, Immunology, 60(1):141-6; and EP 0 549 074 B1). A preferred form of 3D-MPL is in the form of a particulate formulation having a small particle size less than 0.2µm in diameter, and its method of manufacture is disclosed in EP 0 689 454.

Saponins are also preferred Th1 immunostimulants in accordance with the invention. Saponins are well known adjuvants and are taught in: Lacaille-Dubois, M and Wagner H. (1996. A review of the biological and pharmacological activities of saponins. Phytomedicine vol 2 pp 363-386). For example, Quil A (derived from the bark of the South American tree Quillaja Saponaria Molina), and fractions thereof, are described in US 5,057,540 and "Saponins as vaccine adjuvants", Kensil, C. R., Crit Rev Ther Drug Carrier Syst, 1996, 12 (1-2):1-55; and EP 0 362 279 B1. The haemolytic saponins QS21 and QS17 (HPLC purified fractions of Quil A) have been described as potent systemic adjuvants, and the method of their production is disclosed in US Patent No. 5,057,540 and EP 0 362 279 B1. Also described in these references is the use of QS7 (a non-haemolytic fraction of Quil-A) which acts as a potent adjuvant for systemic vaccines. Use of QS21 is further described in Kensil et al. (1991. J.

Immunology vol 146, 431-437). Combinations of QS21 and polysorbate or cyclodextrin are also known (WO 99/10008). Particulate adjuvant systems comprising fractions of QuilA, such as QS21 and QS7 are described in WO 96/33739 and WO 96/11711.

Another preferred immunostimulant is an immunostimulatory oligonucleotide containing unmethylated CpG dinucleotides ("CpG"). CpG is an abbreviation for cytosine-guanosine dinucleotide motifs present in DNA. CpG is known in the art as being an adjuvant when administered by both systemic and mucosal routes (WO 96/02555, EP 468520, Davis et al., J. Immunol, 1998, 160(2):870-876; McCluskie and Davis, J.Immunol., 1998, 161(9):4463-6). Historically, it was observed that the DNA fraction of BCG could exert an anti-tumour effect. In further studies, synthetic oligonucleotides derived from BCG gene sequences were shown to be capable of inducing immunostimulatory effects (both in vitro and in vivo). The authors of these studies concluded that certain palindromic sequences, including a central CG motif, carried this activity. The central role of the CG motif in immunostimulation was later elucidated in a publication by Krieg, Nature 374, p546 1995. Detailed analysis has shown that the CG motif has to be in a certain sequence context, and that such sequences are common in bacterial DNA but are rare in vertebrate DNA. The immunostimulatory sequence is often: Purine, Purine, C, G, pyrimidine, pyrimidine; wherein the CG motif is not methylated, but other unmethylated CpG sequences are known to be immunostimulatory and may be used in the present invention.

In certain combinations of the six nucleotides a palindromic sequence is present. Several of these motifs, either as repeats of one motif or a combination of different motifs, can be present in the same oligonucleotide. The presence of one or more of these immunostimulatory sequences containing oligonucleotides can activate various immune subsets, including natural killer cells (which produce interferon γ and have cytolytic activity) and macrophages (Wooldrige et al Vol 89 (no. 8), 1977). Other unmethylated CpG containing sequences not having this consensus sequence have also now been shown to be immunomodulatory.

CpG when formulated into vaccines, is generally administered in free solution together with free antigen (WO 96/02555; McCluskie and Davis, *supra*) or covalently conjugated to an antigen (WO 98/16247), or formulated with a carrier such as aluminium hydroxide ((Hepatitis surface antigen) Davis *et al. supra*; Brazolot-Millan *et al.*, *Proc.Natl.Acad.Sci.*, USA, 1998, 95(26), 15553-8).

Such immunostimulants as described above may be formulated together with carriers, such as for example liposomes, oil in water emulsions, and or metallic salts, including aluminium salts (such as aluminium hydroxide). For example, 3D-MPL may be formulated with aluminium hydroxide (EP 0 689 454) or oil in water emulsions (WO 95/17210); QS21 may be advantageously formulated with cholesterol containing liposomes (WO 96/33739), oil in water emulsions (WO 95/17210) or alum (WO 98/15287); CpG may be formulated with alum (Davis et al. supra; Brazolot-Millan supra) or with other cationic carriers.

Combinations of immunostimulants are also preferred, in particular a combination of a monophosphoryl lipid A and a saponin derivative (WO 94/00153; WO 95/17210; WO 96/33739; WO 98/56414; WO 99/12565; WO 99/11241), more particularly the combination of QS21 and 3D-MPL as disclosed in WO 94/00153. Alternatively, a combination of CpG plus a saponin such as QS21 also forms a potent adjuvant for use in the present invention.

Thus, suitable adjuvant systems include, for example, a combination of monophosphoryl lipid A, preferably 3D-MPL, together with an aluminium salt. An enhanced system involves the combination of a monophosphoryl lipid A and a saponin derivative particularly the combination of QS21 and 3D-MPL as disclosed in WO 94/00153, or a less reactogenic composition where the QS21 is quenched in cholesterol containing liposomes (DQ) as disclosed in WO 96/33739.

A particularly potent adjuvant formulation involving QS21, 3D-MPL & tocopherol in an oil in water emulsion is described in WO 95/17210 and is another preferred formulation for use in the invention.

Another preferred formulation comprises a CpG oligonucleotide alone or together with an aluminium salt

In another aspect of the invention, the vaccine may contain DNA encoding one or more of the Tat. Nef and gp120 polypeptides, such that the polypeptide is generated in situ. The DNA may be present within any of a variety of delivery systems known to those of ordinary skill in the art, including nucleic acid expression systems such as plasmid DNA, bacteria and viral expression systems. Numerous gene delivery techniques are well known in the art, such as those described by Rolland, Crit. Rev. Therap. Drug Carrier Systems 15:143-198, 1998 and references cited therein. Appropriate nucleic acid expression systems contain the necessary DNA sequences for expression in the patient (such as a suitable promoter and terminating signal). When the expression system is a recombinant live microorganism, such as a virus or bacterium, the gene of interest can be inserted into the genome of a live recombinant virus or bacterium. Inoculation and in vivo infection with this live vector will lead to in vivo expression of the antigen and induction of immune responses. Viruses and bacteria used for this purpose are for instance: poxviruses (e.g. vaccinia, fowlpox, canarypox, modified poxyiruses e.g. Modified Virus Ankara (MVA)), alphaviruses (Sindbis virus, Semliki Forest Virus, Venezuelian Equine Encephalitis Virus), flaviviruses (vellow fever virus, Dengue virus, Japanese encephalitis virus), adenoviruses, adeno-associated virus, picornaviruses (poliovirus, rhinovirus), herpesviruses (varicella zoster virus, etc), Listeria, Salmonella , Shigella, Neisseria, BCG. These viruses and bacteria can be virulent, or attenuated in various ways in order to obtain live vaccines. Such live vaccines also form part of the invention.

Thus, the Nef, Tat and gp120 components of a preferred vaccine according to the invention may be provided in the form of polynucleotides encoding the desired proteins.

Furthermore, immunisations according to the invention may be performed with a combination of protein and DNA-based formulations. Prime-boost immunisations are considered to be effective in inducing broad immune responses. Adjuvanted protein vaccines induce mainly antibodies and T helper immune responses, while delivery of DNA as a plasmid or a live vector induces strong cytotoxic T lymphocyte (CTL)

responses. Thus, the combination of protein and DNA vaccination will provide for a wide variety of immune responses. This is particularly relevant in the context of HIV, since both neutralising antibodies and CTL are thought to be important for the immune defence against HIV.

In accordance with the invention a schedule for vaccination with gp120, Nef and Tat, alone or in combination, may comprise the sequential ("prime-boost") or simultaneous administration of protein antigens and DNA encoding the above-mentioned proteins. The DNA may be delivered as plasmid DNA or in the form of a recombinant live vector, e.g. a poxvirus vector or any other suitable live vector such as those described herein. Protein antigens may be injected once or several times followed by one or more DNA administrations, or DNA may be used first for one or more administrations followed by one or more protein immunisations.

A particular example of prime-boost immunisation according to the invention involves priming with DNA in the form of a recombinant live vector such as a modified poxvirus vector, for example Modified Virus Ankara (MVA) or a alphavirus, for example Venezuelian Equine Encephalitis Virus followed by boosting with a protein, preferably an adjuvanted protein.

Thus the invention further provides a pharmaceutical kit comprising:

- a) a composition comprising one or more of gp120, Nef and Tat proteins together with a pharmaceutically acceptable excipient; and
- a composition comprising one or more of gp120, Nef and Tat-encoding
 polynucleotides together with a pharmaceutically acceptable excipient;
 with the proviso that at least one of (a) or (b) comprises gp120 with Nef and/or Tat
 and/or Nef-Tat

Compositions a) and b) may be administered separately, in any order, or together. Preferably a) comprises all three of gp120, Nef and Tat proteins. Preferably b) comprises all three of gp120, Nef and Tat DNA. Most preferably the Nef and Tat are in the form of a NefTat fusion protein.

In a further aspect of the present invention there is provided a method of manufacture of a vaccine formulation as herein described, wherein the method comprises admixing

a combination of proteins according to the invention. The protein composition may be mixed with a suitable adjuvant and, optionally, a carrier.

Particularly preferred adjuvant and/or carrier combinations for use in the formulations according to the invention are as follows:

- i) 3D-MPL + QS21 in DQ
- ii) Alum + 3D-MPL
- iii) Alum + QS21 in DQ + 3D-MPL
- iv) Alum + CpG
- v) 3D-MPL + QS21 in DQ + oil in water emulsion
- vi) CpG

The invention is illustrated in the accompanying examples and Figures:

EXAMPLES

General

The Nef gene from the Bru/Lai isolate (Cell 40: 9-17, 1985) was selected for the constructs of these experiments since this gene is among those that are most closely related to the consensus Nef.

The starting material for the Bru/Lai Nef gene was a 1170bp DNA fragment cloned on the mammalian expression vector pcDNA3 (pcDNA3/Nef).

The Tat gene originates from the BH10 molecular clone. This gene was received as an HTLV III cDNA clone named pCV1 and described in Science, 229, p69-73, 1985.

The expression of the Nef and Tat genes could be in Pichia or any other host.

Example 1. EXPRESSION OF HIV-1 nef AND tat SEQUENCES IN PICHIA PASTORIS

Nef protein, Tat protein and the fusion Nef-Tat were expressed in the methylotrophic yeast *Pichia pastoris* under the control of the inducible alcohol oxidase (AOXI) promoter.

To express these HIV-1 genes a modified version of the integrative vector PHIL-D2 (INVITROGEN) was used. This vector was modified in such a way that expression of heterologous protein starts immediately after the native ATG codon of the AOX1 gene and will produce recombinant protein with a tail of one glycine and six histidines residues. This PHIL-D2-MOD vector was constructed by cloning an oligonucleotide linker between the adjacent AsuII and EcoRI sites of PHIL-D2 vector (see Figure 2). In addition to the His tail, this linker carries NcoI, Spel and XbaI restriction sites between which nef, tat and nef-tat fusion were inserted.

1.1 CONSTRUCTION OF THE INTEGRATIVE VECTORS pRIT14597 (encoding Nef-His protein), pRIT14598 (encoding Tat-His protein) and pRIT14599 (encoding fusion Nef-Tat-His).

The nef gene was amplified by PCR from the pcDNA3/Nef plasmid with primers 01 and 02.

NcoI

PRIMER 01 (Seq ID NO 1): 5'ATCGTCCATG.GGT.GGC.AAG.TGG.T 3'

SpeI

PRIMER 02 (Seq ID NO 2): 5' CGGCTACTAGTGCAGTTCTTGAA 3'

The PCR fragment obtained and the integrative PHIL-D2-MOD vector were both restricted by Ncol and Spel, purified on agarose gel and ligated to create the integrative plasmid pRIT14597 (see Figure 2).

The tat gene was amplified by PCR from a derivative of the pCV1 plasmid with primers 05 and 04:

SpeI

PRIMER 04 (Seq ID NO 4): 5' CGGCTACTAGTTTCCTTCGGGCCT 3'

NcoI

PRIMER 05 (Seq ID NO 5): 5'ATCGTCCATGGAGCCAGTAGATC 3'

An NcoI restriction site was introduced at the 5' end of the PCR fragment while a SpeI site was introduced at the 3' end with primer 04. The PCR fragment obtained

and the PHIL-D2-MOD vecto: were both restricted by NcoI and SpeI, purified on agarose gel and ligated to create the integrative plasmid pRIT14598.

To construct pRIT14599, a 910bp DNA fragment corresponding to the nef-tat-His coding sequence was ligated between the EcoRI blunted(T4 polymerase) and NcoI sites of the PHIL-D2-MOD vector. The nef-tat-His coding fragment was obtained by XbaI blunted(T4 polymerase) and NcoI digestions of pRIT14596.

1.2 TRANSFORMATION OF PICHIA PASTORIS STRAIN GS115(his4).

To obtain *Pichia pastoris* strains expressing Nef-His, Tat-His and the fusion Nef-Tat-His, strain GS115 was transformed with linear NotI fragments carrying the respective expression cassettes plus the HIS4 gene to complement his4 in the host genome. Transformation of GS115 with NotI-linear fragments favors recombination at the AOXI locus.

Multicopy integrant clones were selected by quantitative dot blot analysis and the type of integration, insertion (Mut*phenotype) or transplacement (Mut*phenotype), was determined.

From each transformation, one transformant showing a high production level for the recombinant protein was selected:

Strain Y1738 (Mut⁺ phenotype) producing the recombinant Nef-His protein, a myristylated 215 amino acids protein which is composed of:

°Myristic acid

°A methionine, created by the use of NcoI cloning site of PHIL-D2-MOD vector

°205 a.a. of Nef protein(starting at a.a.2 and extending to a.a.206)

A threonine and a serine created by the cloning procedure (cloning at SpeI site of PHIL-D2-MOD vector.

One glycine and six histidines.

Strain Y1739 (Mut⁺ phenotype) producing the Tat-His protein, a 95 amino acid protein which is composed of:

°A methionine created by the use of NcoI cloning site
°85 a.a. of the Tat protein(starting at a.a.2 and extending to a.a.86)

oA threonine and a serine introduced by cloning procedure

One glycine and six histidines

Strain Y1737(Mut^s phenotype) producing the recombinant Nef-Tat-His fusion protein, a myristylated 302 amino acids protein which is composed of:

°Myristic acid

°A methionine, created by the use of NcoI cloning site

°205a.a. of Nef protein(starting at a.a.2 and extending to a.a.206)

°A threonine and a serine created by the cloning procedure

°85a.a. of the Tat protein(starting at a.a.2 and extending to a.a.86)

°A threonine and a serine introduced by the cloning procedure

One glycine and six histidines

Example 2. EXPRESSION OF HIV-1 Tat-MUTANT IN PICHIA PASTORIS

A mutant recombinant Tat protein has also been expressed. The mutant Tat protein must be biologically inactive while maintaining its immunogenic epitopes.

A double mutant *tat* gene, constructed by D.Clements (Tulane University) was selected for these constructs.

This tat gene (originates from BH10 molecular clone) bears mutations in the active site region (Lys41→Ala)and in RGD motif (Arg78→Lys and Asp80→Glu) (Virology 235: 48-64, 1997).

The mutant tat gene was received as a cDNA fragment subcloned between the EcoRI and HindIII sites within a CMV expression plasmid (pCMVLys41/KGE)

2.1 CONSTRUCTION OF THE INTEGRATIVE VECTORS pRIT14912(encoding Tat mutant-His protein) and pRIT14913(encoding fusion Nef-Tat mutant-His).

The tat mutant gene was amplified by PCR from the pCMVLys41/KGE plasmid with primers 05 and 04 (see section 1.1construction of pRIT14598)

An Ncol restriction site was introduced at the 5' end of the PCR fragment while a Spel site was introduced at the 3' end with primer 04. The PCR fragment obtained and the PHIL-D2-MOD vector were both restricted by Ncol and Spel, purified on agarose gel and ligated to create the integrative plasmid pRIT14912

To construct pRIT14913, the *tat* mutant gene was amplified by PCR from the pCMVLys41/KGE plasmid with primers 03 and 04.

SpeI

PRIMER 03 (Seq ID NO 3): 5' ATCGTACTAGT.GAG.CCA.GTA.GAT.C 3'

SpeI

PRIMER 04 (Seq ID NO 4): 5' CGGCTACTAGTTTCCTTCGGGCCT 3'

The PCR fragment obtained and the plasmid pRIT14597 (expressing Nef-His protein) were both digested by Spel restriction enzyme, purified on agarose gel and ligated to create the integrative plasmid pRIT14913

2.2 TRANSFORMATION OF PICHIA PASTORIS STRAIN GS115.

<u>Pichia pastoris</u> strains expressing Tat mutant-His protein and the fusion Nef-Tat mutant-His were obtained, by applying integration and recombinant strain selection strategies previously described in section 1.2.

Two recombinant strains producing Tat mutant-His protein ,a 95 amino-acids protein, were selected: Y1775 (Mut⁺ phenotype) and Y1776(Mut⁺ phenotype).

One recombinant strain expressing Nef-Tat mutant-His fusion protein, a 302 aminoacids protein was selected: Y1774(Mut* phenotype).

Example 3: FERMENTATION OF PICHIA PASTORIS PRODUCING RECOMBINANT TAT-HIS.

A typical process is described in the table hereafter.

Fermentation includes a growth phase (feeding with a glycerol-based medium according to an appropriate curve) leading to a high cell density culture and an induction phase (feeding with a methanol and a salts/micro-elements solution). During fermentation the growth is followed by taking samples and measuring their absorbance at 620 nm. During the induction phase methanol was added via a pump and its concentration monitored by Gas chromatography (on culture samples) and by on-line gas analysis with a Mass spectrometer. After fermentation the cells were recovered by centrifugation at 5020g during 30° at 2-8°C and the cell paste stored at – 20°C. For further work cell paste was thawed, resuspended at an OD (at 620 nm) of 150 in a buffer (Na2HPO4 pH7 50 mM, PMSF 5%, Isopropanol 4 mM) and disrupted by 4 passages in a DynoMill (room 0.6L, 3000 rpm, 6L/H, beads diameter of 0.40-0.70 mm).

For evaluation of the expression samples were removed during the induction, disrupted and analyzed by SDS-Page or Western blot. On Coomassie blue stained SDS-gels the recombinant Tat-his was clearly identified as an intense band presenting a maximal intensity after around 72-96H induction.

Thawing of a Working seed vial			
4			
Solid preculture	Synthetic medium: YNB + glucose + agar		
30°C, 14-16H			
V			
Liquid preculture in two 2L erlenmeyer	Synthetic medium: 2 x 400 ml YNB + glycerol		
30°C, 200 rpm	Stop when OD > 1 (at 620 nm)		
+			
Inoculation of a 20L fermentor	5L initial medium (FSC006AA)		
	3 ml antifoam SAG471 (from Witco)		
	Set-points: Temperature : 30°C		
	Overpressure: 0.3 barg		
	Air flow: 20 NI/min		
	Dissolved O2: regulated > 40%		
	pH : regulated at 5 by NH4OH		
*			
Fed-batch fermentation: growth phase	Feeding with glycerol-based medium FFB005AA		
Duration around 40H,	Final OD between 200-500 OD (620 nm)		
Fed-batch fermentation: induction phase Duration: up to 97H.	Feeding with methanol and with a salt/micro-elements solution (FSE021AB).		
Ψ			
Centrifugation	5020g /30 min / 2-8°C		
ψ			
Recover cell paste and store at -20°C			
Ψ			
Thaw cells and resuspend at OD150 (620 nm) in buffer	Buffer: Na2HPO4 pH7 50 mM, PMSF 5%, Isopropanol 4 mM		
4			
Cell disruption in Dyno-mill	Dyno-mill: (room 0.6L, 3000 rpm, 6L/H, beads		
4 passages	diameter of 0.40-0.70 mm).		
+			
Transfer for extraction/purification			
	L		

Media used for fermentation:

Solid preculture	: (YNB + gluco	se + agar)			
Glucose:	10 g/l	Na2MoO4.2H2O:	0.0002 g/I	Acide folique:	0.000064 g/
KH2PO4:	lg/l	MnSO4.H2O:	0.0004 g/l	Inositol:	0.064 g/l
MgSO4.7H2O:	0.5 g/l	H3BO3:	0.0005 g/l	Pyridoxine:	0.008 g/I
CaC12.2H2O:	0.1 g/l	KI;	0.0001 g/l	Thiamine:	0.008 g/I
NaCl:	0.1 g/I	CoCl2.6H2O:	0.00009 g/l	Niacine:	0.000032 g/
FeC13.6H2O:	0.0002 g/l	Riboflavine:	0.000016 g/l	Panthoténate Ca:	0.008 g/l
CuSO4.5H2O:	0.00004 g/l	Biotine:	0.000064 g/l	Para-aminobenzoic acid:	0.000016 g/
ZnSO4.7H2O:	0.0004 g/l	(NH4)2SO4:	5 g/l	Agar	18 g/l

Glycerol:	2% (v/v)	Na2MoO4.2H2O:	0.0002 g/l	Acide folique:	0.000064 g/
KH2PO4:	1 g/l	MnSO4.H2O:	0.0004 g/l	Inositol:	0.064 g/I
MgSO4.7H2O:	0.5 g/l	H3BO3:	0.0005 g/l	Pyridoxine:	0.008 g/I
CaC12.2H2O:	0.1 g/l	KI:	0.0001 g/l	Thiamine:	0.008 g/I
NaCl:	0.1 g/l	CoC12.6H2O:	0.00009 g/l	Niacine:	0.000032 g/
FeC13.6H2O:	0.0002 g/l	Riboflavine:	0.000016 g/l	Panthoténate Ca:	0.008 g/l
CuSO4.5H2O:	0.00004 g/l	Biotine:	0.000064 g/l	Para-aminobenzoic acid:	0.000016 g/
ZnSO4.7H2O:	0.0004 g/l	(NH4)2SO4:	5 g/l		

Initial fermente	or charge: (FSC006AA)		
(NH4) ₂ SO4:	6.4 g/l		
KH2PO4:	9 g/l	Na2MoO4.2H2O:	2.04 mg/l
MgSO4.7H2O:	4.7 g/l	MnSO4.H2O:	4.08 mg/l
CaCl2.2H2O:	0.94 g/l	H3BO3:	5.1 mg/l
FeCl3.6H2O:	10 mg/l	KI:	1.022 mg/l
HCI:	1.67 ml/l	CoCl2.6H2O:	0.91mg/l
CuSO4.5H2O:	0.408 mg/l	NaCl:	0.06 g/l
ZnSO4.7H2O:	4.08 mg/l	Biotine:	0.534 mg/l

Feeding solution	used for growth phase (FFB005AA)		
Glycérol:	38.7 % v/v	Na2MoO4.2H2O:	5.7 mg/l
MgSO4.7H2O:	13 g/l	CuSO4.5H2O:	1.13 mg/l
CaCl2.2H2O:	2.6 g/1	CoCl2.6H2O:	2.5 mg/l
FeC13.6H2O:	27.8mg/l	H3BO3:	14.2 mg/l
ZnSO4.7H2O	11.3 mg/l	Biotine:	1.5 mg/l
MnSO4.H2O:	11.3 mg/l	KI:	2.84mg/l
KH2PO4:	24.93 g/l	NaCl:	0.167 g/l

Feeding solutio	n of salts and micr	o-elements used during indu	ction (FSE021AB):
KH2PO4:	45 g/l	Na2MoO4.2H2O:	10.2 mg/l
MgSO4.7H2O:	23.5 g/l .	MnSO4.H2O:	20.4 mg/l
CaC12.2H2O:	4.70 g/l	H3BO3:	25.5 mg/l
NaCl:	0.3 g/l	K1:	5.11 mg/l
HCl:	8.3 ml/l	CoCl2.6H2O:	4.55mg/l
CuSO4.5H2O:	2.04 mg/l	FeCl3.6H2O:	50.0 mg/l
ZnSO4.7H2O:	20.4 mg/l	Biotine:	2.70 mg/l

Example 4: PURIFICATION OF Nef-Tat-His FUSION PROTEIN (PICHIA PASTORIS)

The purification scheme has been developed from 146g of recombinant Pichia pastoris cells (wet weight) or 2L. Dyno-mill homogenate OD 55. The chromatographic steps are performed at room temperature. Between steps, Nef-Tat positive fractions are kept overnight in the cold room (+4°C); for longer time, samples are frozen at -20°C.

146g of Pichia pastoris cells

4

Homogenization

Buffer: 2L 50 mM PO₄ pH 7.0

final OD:50

V

Dyno-mill disruption (4 passes)

J

Centrifugation

JA10 rotor / 9500 rpm/ 30 min /

room temperature

₩

Dyno-mill Pellet

 Ψ

Wash (1h - 4°C) Buffer: +2L 10 mM PO4 pH 7.5 -

150mM - NaCl 0,5% empigen

 \downarrow

Centrifugation JA10 rotor / 9500 rpm/ 30 min /

room temperature

J

Pellet

.

Solubilisation Buffer: + 660ml 10 mM PO₄ pH

(O/N - 4°C) 7.5 - 150mM NaCl - 4.0M GuHCl

Reduction

(4H - room temperature - in the dark) acid, so

+ 0,2M 2-mercaptoethanesulfonic acid, sodium salt (powder addition) / pH adjusted to 7.5 (with 0,5M NaOH solution) before incubation

V

carbamidomethylation

(1/2 h - room temperature - in the dark)

+ 0,25M Iodoacetamide (powder addition) / pH adjusted to 7.5 (with 0,5M NaOH solution) before incubation

J

Immobilized metal ion affinity chromatography on Ni⁺⁺-NTA-Agarose (Qiagen - 30 ml of resin) Equilibration buffer: 10 mM PO₄ pH 7.5 - 150mM NaCl - 4.0M GuHCl

Washing buffer: 1) Equilibration buffer

2) 10 mM PO₄ pH 7.5 - 150mM NaCl - 6M Urea

3) 10 mM PO₄

pH 7.5 - 150mM NaCl - 6M Urea

- 25 mM Imidazol

Elution buffer: 10 mM PO₄ pH 7.5 - 150mM NaCl - 6M Urea - 0,5M

Imidazol

Dilution Down to an ionic strength of 18

mS/cm²

Dilution buffer: 10 mM PO₄ pH

7.5 - 6M Urea

 \downarrow

Cation exchange chromatography on SP

Sepharose FF
(Pharmacia - 30 ml of resin)

Equilibration buffer: 10 mM PO₄

pH 7.5 - 150mM NaCl - 6.0M

Urea

Washing buffer: 1) Equilibration

buffer

2) 10 mM PO₄

pH 7.5 - 250mM NaCl - 6M Urea

Elution buffer: 10 mM Borate pH

9.0 - 2M NaCl - 6M Urea

Concentration

up to 5 mg/ml

10kDa Omega membrane(Filtron)

d

Gel filtration chromatography on

Superdex200 XK 16/60

(Pharmacia - 120 ml of resin)

Elution buffer: 10 mM PO₄ pH 7.5

- 150mM NaCl - 6M Urea
5 ml of sample / injection → 5

injections

 Ψ

Dialysis
(O/N - 4°C)

Buffer: 10 mM PO₄ pH 6.8 -150mM NaCl - 0,5M Arginin*

J.

Sterile filtration

Millex GV 0,22µm

* ratio: 0,5M Arginin for a protein concentration of 1600µg/ml.

Purity

The level of purity as estimated by SDS-PAGE is shown in Figure 3 by Daiichi Silver Staining and in Figure 4 by Coomassie blue G250.

After Superdex200 step:

> 95%

After dialysis and sterile filtration steps:

> 95%

Recovery

51mg of Nef-Tat-his protein are purified from 146g of recombinant Pichia pastoris cells (= 2L of Dyno-mill homogenate OD 55)

Example 5: PURIFICATION OF OXIDIZED NEF-TAT-HIS FUSION PROTEIN IN PICHIA PASTORIS

The purification scheme has been developed from 73 g of recombinant Pichia pastoris cells (wet weight) or 1 L Dyno-mill homogenate OD 50. The chromatographic steps are performed at room temperature. Between steps, Nef-Tat positive fractions are kept overnight in the cold room (+4°C); for longer time, samples are frozen at -20°C.

73 g of Pichia pastoris cells

١.

Homogenization

Buffer: 1L 50 mM PO₄ pH 7.0-

Pefabloc 5 mM

final OD:50

J.

Dyno-mill disruption (4 passes)

/

Centrifugation	JA10 rotor / 9500 rpm/ 30 min / room temperature		
Ψ			
Dyno-mill Pellet			
4			
Wash	Buffer: +1L 10 mM PO ₄ pH 7.5 – 150		
(2h - 4°C)	mM NaCl - 0,5% Empigen		
4			
Centrifugation	JA10 rotor / 9500 rpm/ 30 min / room temperature		
Ψ			
Pellet			
Ψ			
Solubilisation	Buffer: + 330ml 150mM NaCl -	1 10 mM PO ₄ pH 7.5 -	
(O/N - 4°C)	150iller Naci	4.0M Guilei	
Ψ		m 40 MDO W7.5	
Immobilized metal ion affinity chromatography on Ni ⁺⁺ -NTA-Agarose	Equilibration buffer: 10 mM PO ₄ pH 7.5 - 150 mM NaCl - 4.0 M GuHCl		
(Qiagen - 15 ml of resin)	Washing buffer: 1) Equilibration buffe		
	– Urea	2) 10 mM PO ₄ pH 7.5 150 mM NaCl – 6 M	
	– Urea -	3) 10 mM PO ₄ pH 7.5 150 mM NaCl – 6 M 25 mM Imidazol	
	Elution buffer: 10 mM PO ₄ pH 7.5 – 150 mM NaCl – 6 M Urea - 0,5 M Imidazol		
V			
Dilution	Down to an ionic strength of 18 mS/cm ²		
	Dilution buffer: M Urea	10 mM PO ₄ pH 7.5 – 6	
Cation exchange chromatography on SP Sepharose FF	Equilibration buffer: 10 mM PO ₄ pH 7.5 – 150 mM NaCl - 6.0 M Urea		
(Pharmacia - 7 ml of resin)	Washing buffer	: 1) Equilibration buffer	
	- Urea	2) 10 mM PO ₄ pH 7.5 250 mM NaCl – 6 M	

Elution buffer: 10 mM Borate pH 9.0 - 2 M NaCl - 6 M Urea

Concentration

up to 0,8 mg/ml

Concentration

10kDa Omega membrane(Filtron)

Dialysis

Buffer: 10 mM PO₄ pH 6.8 - 150 mM

(O/N - 4°C)

NaCl - 0,5 M Arginin

Sterile filtration

Millex GV 0,22μm

→ Level of purity estimated by SDS-PAGE is shown in Figure 6 (Daiichi Silver Staining, Coomassie blue G250, Western blotting):

After dialysis and sterile filtration steps: > 95%

→ Recovery (evaluated by a colorimetric protein assay: DOC TCA BCA)

2,8 mg of oxidized Nef-Tat-his protein are purified from 73 g of recombinant Pichia pastoris cells (wet weight) or 1 L of Dyno-mill homogenate OD 50.

Example 6: PURIFICATION OF REDUCED TAT-HIS PROTEIN (PICHIA PASTORIS)

The purification scheme has been developed from 160 g of recombinant Pichia pastoris cells (wet weight) or 2L Dyno-mill homogenate OD 66. The chromatographic steps are performed at room temperature. Between steps, Tat positive fractions are kept overnight in the cold room (+4°C); for longer time, samples are frozen at -20°C.

160 g of Pichia pastoris cells Homogenization Buffer: +2 L 50 mM PO4 pH 7.0 - 4 mM PMSF final OD:66 Dyno-mill disruption (4 passes) Centrifugation JA10 rotor / 9500 rpm / 30 min / room temperature Dyno-mill Pellet ┺ Wash Buffer: +2 L 10 mM PO4 pH 7.5 - 150 mM NaCl - 1% Empigen (1h - 4°C) T Centrifugation JA10 rotor / 9500 rpm / 30 min / room temperature Ť Pellet Ŧ Solubilisation Buffer: + 660 ml 10 mM PO₄ pH 7.5 - 150 mM NaCl - 4.0 M GuHCl (O/N - 4°C) Centrifugation JA10 rotor / 9500 rpm / 30 min / room temperature Reduction + 0.2 M 2-mercaptoethanesulfonic acid, sodium salt (powder addition) / pH adjusted to 7.5 (with (4H - room temperature - in the dark) 1 M NaOH solution) before incubation carbamidomethylation + 0,25 M Iodoacetamide (powder addition) / pH adjusted to 7.5 (with 1 M NaOH solution) before (1/2 h - room temperature - in the dark) incubation Immobilized metal ion affinity Equilibration buffer: 10 mM PO₄ pH 7.5 - 150 mM chromatography on Ni⁺⁺-NTA-Agarose NaCl - 4.0 M GuHCl (Qiagen - 60 ml of resin) Washing buffer: 1) Equilibration buffer 2) 10 mM PO₄ pH 7.5 - 150 mM

NaCl - 6 M Urea 3) 10 mM PO₄ pH 7.5 - 150 mM

NaCl - 6M Urea - 35 mM

Imidazol

Elution buffer: 10 mM PO₄ pH 7.5 - 150 mM NaCl

- 6 M Urea - 0,5 M Imidazol

 $\mathbf{\Psi}$

Dilution Down to an ionic strength of 12 mS/cm

Dilution buffer: 20 mM Borate pH 8.5 - 6 M Urea

J

Cation exchange chromatography on SP Sepharose FF

Equilibration buffer: 20 mM Borate pH 8.5 -150 mM NaCl - 6.0 M Urea

(Pharmacia - 30 ml of resin)

Washing buffer: Equilibration buffer
Elution buffer: 20 mM Borate pH 8.5 – 400 mM

NaCl - 6.0 M Urea

 $\mathbf{\Psi}$

Concentration

up to 1,5 mg/ml

10kDa Omega membrane(Filtron)

✓

Dialysis

Buffer: 10 mM PO₄ pH 6.8 – 150 mM NaCl - 0,5 M Arginin

(O/N - 4°C)

Sterile filtration

Millex GV 0,22 µm

→ Level of purity estimated by SDS-PAGE as shown in Figure 7(Daiichi Silver Staining, Coomassie blue G250, Western blotting):

After dialysis and sterile filtration steps: > 95%

→ Recovery (evaluated by a colorimetric protein assay: DOC TCA BCA)

48 mg of reduced Tat-his protein are purified from 160 g of recombinant Pichia pastoris cells (wet weight) or 2 L of Dyno-mill homogenate OD 66.

Example 7: Purification of oxidized Tat-his protein (Pichia Pastoris)

The purification scheme has been developed from 74 g of recombinant Pichia pastoris cells (wet weight) or 1L Dyno-mill homogenate OD60. The chromatographic steps are performed at room temperature. Between steps, Tat positive fractions are kept overnight in the cold room (+4°C); for longer time, samples are frozen at -20°C.

74 g of Pichia pastoris cells Homogenization Buffer: +1 L 50 mM PO4 pH 7.0 - 5 mM Pefabloc final OD:60 Dyno-mill disruption (4 passes) Centrifugation JA10 rotor / 9500 rpm / 30 min / room temperature ₽ Dyno-mill Pellet Ψ Wash Buffer:+1 L 10 mM PO4 pH 7.5 - 150 mM NaCl - 1% Empigen (lh - 4°C) ┰ Centrifugation JA10 rotor / 9500 rpm / 30 min / room temperature J Pellet Ψ Solubilisation Buffer: + 330 ml 10 mM PO₄ pH 7.5 - 150 mM NaCl - 4.0 M GuHCl (O/N - 4°C) ₩ Centrifugation JA10 rotor / 9500 rpm / 30 min / room temperature Ψ

Immobilized metal ion affinity chromatography on Ni⁺⁺-NTA-Agarose (Qiagen - 30 ml of resin) Equilibration buffer: 10 mM PO₄ pH 7.5 –150 mM NaCl - 4.0 M GuHCl

Washing buffer: 1) Equilibration buffer

2) 10 mM PO₄ pH 7.5 - 150 mM NaCl - 6 M Urea

3) 10 mM PO₄ pH 7.5 - 150 mM NaCl - 6 M Urea - 35 mM Imidazol

Elution buffer: 10 mM PO₄ pH 7.5 – 150 mM NaCl – 6 M Urea - 0.5 M Imidazol

Dilution Down to an ionic strength of 12 mS/cm

Dilution buffer: 20 mM Borate pH 8.5 - 6 M Urea

Cation exchange chromatography on SP Equilibration buffer: 20 mM Borate pH 8.5 - Sepharose FF 150 mM NaCl - 6.0 M Urea

(Pharmacia - 15 ml of resin) Washing buffer: 1) Equilibration buffer 2) 20 mM Borate pH 8.5 -

400 mM NaCl - 6.0 M Urea

Elution buffer: 20 mM Piperazine pH 11.0 – 2 M
NaCl – 6 M Urea

Ψ

Concentration up to 1.5 mg/ml

10 kDa Omega membrane(Filtron)

Dialysis

Buffer: 10 mM PO₄ pH 6.8 - 150 mM NaCl -0,5 M Arginin

4

Sterile filtration Millex GV 0,22 µm

→ Level of purity estimated by SDS-PAGE as shown in Figure 8 (Daiichi Silver Staining, Coomassie blue G250, Western blotting):

After dialysis and sterile filtration steps: > 95%

→ Recovery (evaluated by a colorimetric protein assay: DOC TCA BCA)

19 mg of oxidized Ta:-his protein are purified from 74 g of recombinant Pichia pastoris cells (wet weight) or 1 L of Dyno-mill homogenate OD 60.

Example 8: PURIFICATION OF SIV REDUCED NEF-HIS PROTEIN (PICHIA PASTORIS)

The purification scheme has been developed from 340 g of recombinant Pichia pastoris cells (wet weight) or 4 L Dyno-mill homogenate OD 100. The chromatographic steps are performed at room temperature. Between steps, Nef positive fractions are kept overnight in the cold room (+4°C); for longer time, samples are frozen at -20°C.

340 g of Pichia pastoris cells

J

Homogenization

Buffer: 4L 50 mM PO4 pH 7.0 - PMSF 4 mM

final OD:100

┵

Dyno-mill disruption (4 passes)

Centrifugation

JA10 rotor / 9500 rpm/ 60 min / room

temperature

Dyno-mill Pellet

•

Solubilisation (O/N - 4°C) Buffer: + 2,6 L 10 mM PO₄ pH 7.5 - 150mM

NaCl - 4.0M GuHCl

Centrifugation

JA10 rotor / 9500 rpm / 30 min / room temperature

 $\mathbf{\Psi}$

Reduction

+ 0,2 M 2-mercaptoethanesulfonic acid, sodium salt (powder addition) / pH adjusted to 7.5 (with

(4H - room temperature - in the dark)

I M NaOH solution) before incubation

+ 0,25 M Iodoacetamide (powder addition) / pH Carbamidomethylation adjusted to 7.5 (with 1 M NaOH solution) (1/2 h - room temperature - in the dark) before incubation

Immobilized metal ion affinity chromatography on Ni -- NTA-Agarose

(Qiagen - 40 ml of resin)

Equilibration buffer: 10 mM PO₄ pH 7.5 - 150 mM NaCl - 4.0 M GuHCl

Washing buffer: 1) Equilibration buffer

> 2) 10 mM PO₄ pH 7.5 -150 mM NaCl - 6 M Urea -25 mM Imidazol

Elution buffer: 10 mM PO4 pH 7.5 - 150 mM

NaCl - 6 M Urea - 0,5 M Imidazol

Concentration up to 3 mg/ml

10kDa Omega membrane(Filtron)

Gel filtration chromatography on Superdex 200

Elution buffer: 10 mM PO₄ pH 7.5 - 150 mM NaCl - 6 M Urea

(Pharmacia - 120 ml of resin)

J

up to 1,5 mg/ml Concentration

10kDa Omega membrane(Filtron)

Dialysis

Buffer: 10 mM PO4 pH 6.8 - 150 mM NaCl -Empigen 0,3%

(O/N - 4°C)

Millex GV 0,22µm

Sterile filtration

→ Level of purity estimated by SDS-PAGE as shown in Figure 9 (Daiichi Silver Staining, Coomassie blue G250, Western blotting):

After dialysis and sterile filtration steps: > 95%

→ Recovery (evaluated by a colorimetric protein assay: DOC TCA BCA)

20 mg of SIV reduced Nef-his protein are purified from 340 g of recombinant Pichia pastoris cells (wet weight) or 4 L of Dyno-mill homogenate OD 100.

Example 9: PURIFICATION OF HIV REDUCED NEF-HIS PROTEIN (PICHIA PASTORIS)

The purification scheme has been developed from 160 g of recombinant Pichia pastoris cells (wet weight) or 3 L Dyno-mill homogenate OD 50. The chromatographic steps are performed at room temperature. Between steps, Nef positive fractions are kept overnight in the cold room (+4°C); for longer time, samples are frozen at -20°C.

160 g of Pichia pastoris cells

 \downarrow

Homogenization

Buffer: 3 L 50 mM PO₄ pH 7.0 - Pefabloc 5 mM final OD:50

 \mathbf{I}

Dyno-mill disruption (4 passes)

 Ψ

Freezing/Thawing

L

Centrifugation

JA10 rotor / 9500 rpm/ 60 min / room

temperature

Dyno-mill Pellet

┵

Solubilisation Buffer: + 1 L 10 mM PO₄ pH 7.5 - 150mM NaCl - 4.0M GuHCl

(O/N - 4°C) NaCl - 4.0M Guf

` J

Centrifugation JA10 rotor / 9500 rpm / 60 min / room temperature

tempera

Ψ

Reduction

(3 H - room temperature - in the dark)

Carbamidomethylation

(1/2 h - room temperature - in the dark)

+ 0,1 M 2-mercaptoethanesulfonic acid, sodium salt (powder addition) / pH adjusted to 7.5 (with 1 M NaOH solution) before incubation

+ 0,15 M Iodoacetamide (powder addition) / pH adjusted to 7.5 (with 1 M NaOH solution)

before incubation

Immobilized metal ion affinity

chromatography on Ni*+-NTA-Agarose (Qiagen - 10 ml of resin)

Equilibration buffer: 10 mM PO₄ pH 7.5 - 150 mM NaCl - 4.0 M GuHCl

Washing buffer: 1) Equilibration buffer

> 2) 10 mM PO₄ pH 7.5 -150 mM NaCl - 6 M Urea 3) 10 mM PO₄ pH 7.5 -150 mM NaCl - 6 M Urea -

25 mM Imidazol Elution buffer: 10 mM Citrate pH 6.0 - 150 mM NaCl - 6 M Urea - 0,5 M Imidazol

Concentration

up to 3 mg/ml

10kDa Omega membrane(Filtron)

Gel filtration chromatography on Superdex 200

(Pharmacia - 120 ml of resin)

J Dialysis

(O/N - 4°C)

J

Elution buffer: 10 mM PO4 pH 7.5 - 150 mM NaCl - 6 M Urea

Buffer: 10 mM PO4 pH 6.8 - 150 mM NaCl -0.5M Arginin

Millex GV 0.22um Sterile filtration

→ Level of purity estimated by SDS-PAGE as shown in Figure 10 (Daiichi Silver Staining, Coomassie blue G250, Western blotting):

After dialysis and sterile filtration steps: > 95%

→ Recovery (evaluated by a colorimetric protein assay: DOC TCA BCA)

20 mg of HIV reduced Nef-his protein are purified from 160 g of recombinant Pichia pastoris cells (wet weight) or 3 L of Dyno-mill homogenate OD 50.

Example 10: EXPRESSION OF SIV nef SEQUENCE IN PICHIA PASTORIS

In order to evaluate Nef and Tat antigens in the pathogenic SHIV challenge model, we have expressed the Nef protein of simian immunodeficiency virus (SIV) of macaques, SIVmac239 (Aids Research and Human Retroviruses, 6:1221-1231,1990).

In the Nef coding region, SIV mac 239 has an in-frame stop codon after 92aa predicting a truncated product of only 10kD. The remainder of the Nef reading frame is open and would be predicted to encode a protein of 263aa (30kD) in its fully open form.

Our starting material for SIVmac239 nef gene was a DNA fragment corresponding to the complete coding sequence, cloned on the LX5N plasmid (received from Dr R.C. Desrosiers, Southborough, MA, USA).

This SIV nef gene is mutated at the premature stop codon (nucleotide G at position 9353 replaces the original T nucleotide) in order to express the full-length SIV mac 239 Nef protein.

To express this SIV nef gene in <u>Pichia pastoris</u>, the PHIL-D2-MOD Vector (previously used for the expression of HIV-1 nef and tat sequences) was used. The recombinant protein is expressed under the control of the inducible alcohol oxidase (AOX1) promoter and the c-terminus of the protein is elongated by a Histidine affinity tail that will facilitate the purification.

10.1 CONSTRUCTION OF THE INTEGRATIVE VECTOR PRIT 14908

To construct pRIT 14908, the SIV nef gene was amplified by PCR from the pLX5N/SIV-NEF plasmid with primers SNEF1 and SNEF2.

PRIMER SNEF1: 5' ATCGT<u>CCATG.G</u>GTGGAGCTATTTT 3'
NcoI

PRIMER SNEF2: 5' CGGCT<u>ACTAGT</u>GCGAGTTTCCTT 3' SpeI

The SIV nef DNA region amplified starts at nucleotide 9077 and terminates at nucleotide 9865 (Aids Research and Human Retroviruses, 6:1221-1231,1990).

An Ncol restriction site (with carries the ATG codon of the nef gene) was introduced at the 5' end of the PCR fragment while a Spel site was introduced at the 3' end. The PCR fragment obtained and the integrative PHIL-D2-MOD vector were both restricted by Ncol and Spel. Since one Ncol restriction site is present on the SIV nef amplified sequence (at position 9286), two fragments of respectively ±200bp and ±600bp were obtained, purified on agarose gel and ligated to PHIL-D2-MOD vector. The resulting recombinant plasmid received, after verification of the nef amplified region by automated sequencing, the pRIT 14908 denomination.

10.2 TRANSFORMATION OF PICHIA PASTORIS STRAIN GS115(his4).

To obtain <u>Pichia pastoris</u> strain expressing SIV nef-His, strain GS115 was transformed with a linear NotI fragment carrying only the expression cassette and the HIS4 gene (Fig.11).

This linear Notl DNA fragment, with homologies at both ends with AOX1 resident *P.pastoris* gene, favors recombination at the AOX1 locus.

Multicopy integrant clones were selected by quantitative dot blot analysis.

One transformant showing the best production level for the recombinant protein was selected and received the Y1772 denomination.

Strain Y1772 produces the recombinant SIV Nef-His protein, a 272 amino acids protein which would be composed of:

°Myristic acid

oA methionine, created by the use of NcoI cloning site of PHIL-D2-MOD vector .

°262 amino acids (aa) of Nef protein (starting at aa 2 and extending to aa 263, see Figure 12)

°A threonine and a serine created by the cloning procedure (cloning at SpeI site of PHIL-D2-MOD vector (Fig.11).

One glycine and six histidines.

Nucleic and Protein sequences are shown on figure 12.

10.3 CHARACTERIZATION OF THE EXPRESSED PRODUCT OF STRAIN Y1772.

Expression level

After 16 hours induction in medium containing 1% methanol as carbon source, abundance of the recombinant Nef-His protein, was estimated at 10% of total protein (Fig.13, lanes 3-4).

Solubility

Induced cultures of recombinant strain Y1772 producing the Neft-His protein were centrifuged. Cell pellets were resuspended in breaking buffer, disrupted with 0.5mm glass beads and the cell extracts were centrifuged. The proteins contained in the insoluble pellet (P) and in the soluble supernatant (S) were compared on a Coomassie Blue stained SDS-PAGE10%.

As shown in figure 13, the majority of the recombinant protein from strain Y1772 (lanes 3-4) is associated with the insoluble fraction.

Strain Y1772 which presents a satisfactory recombinant protein expression level is used for the production and purification of SIV Nef-His protein.

Example 11: EXPRESSION OF GP120 IN CHO

A stable CHO-K1 cell line which produces a recombinant gP120 glycoprotein has been established. Recombinant gP120 glycoprotein is a recombinant truncated form of the gP120 envelope protein of HIV-1 isolate W61D. The protein is excreted into the cell culture medium, from which it is subsequently purified.

Construction of gp120 transfection plasmid pRIT13968

The envelope DNA coding sequence (including the 5'exon of tat and rev) of HIV-1 isolate W61D was obtained (Dr. Tersmette, CCB, Amsterdam) as a genomic gp160 envelope containing plasmid W61D (Nco-XhoI). The plasmid was designated pRIT13965.

In order to construct a gp120 expression cassette a stop codon had to be inserted at the amino acid glu 515 codon of the gp160 encoding sequence in pRIT13965 using a primer oligonucleotide sequence (DIR 131) and PCR technology. Primer DIR 131 contains three stop codons (in all open reading frames) and a Sall restriction site.

The complete gp120 envelope sequence was then reconstituted from the N-terminal BamH1-Dral fragment (170 bp) of a gp160 plasmid subclone pW61d env (pRIT13966) derived from pRIT13965, and the Dral-Sall fragment (510 bp) generated by PCR from pRIT13965. Both fragments were gel purified and ligated together into the E.coli plasmid pDL18, cut first by Sall (klenow treated), and then by BamH1. This resulted in plasmid pRIT13967. The gene sequence of the Xmal-Sall fragment (1580 bp) containing the gp120 coding cassette was sequenced and found to be identical to the predicted sequence. Plasmid RIT13967 was ligated into the CHO GS-expression vector pEE14 (Celltech Ltd., UK) by cutting first with Bell (klenow treated) and then by Xmal. The resulting plasmid was designated pRIT13968.

Preparation of Master Cell Bank

The gp120-construct (pRIT13968) was transfected into CHO cells by the classical CaPO₄-precipitation/glycerol shock procedure. Two days later the CHOK1 cells were subjected to selective growth medium (GMEM + methionine sulfoximine (MSX) 25 µM + Glutamate + asparagine + 10% Foetal calf serum). Three chosen

transfectant clones were further amplified in 175m² flasks and few cell vials were stored at -80°C. C-env 23.9 was selected for further expansion.

A small prebank of cells was prepared and 20 ampoules were frozen. For preparation of the prebank and the MCB, cells were grown in GMEM culture medium, supplemented with 7.5 % fetal calf serum and containing 50 μ M MSX. These cell cultures were tested for sterility and mycoplasma and proved to be negative.

The Master Cell Bank CHOK1 env 23.9 (at passage 12) was prepared using cells derived from the premaster cell bank. Briefly, two ampoules of the premaster seed were seeded in medium supplemented with 7.5% dialysed foetal bovine serum. The cells were distributed in four culture flasks and cultured at 37°C. After cell attachment the culture medium was changed with fresh medium supplemented with 50 µM MSX. At confluence, cells were collected by trypsination and subcultured with a 1/8 split ratio in T-flasks - roller bottle - cell factory units. Cells were collected from cell factory units by trypsination and centrifugation. The cell pellet was resuspended in culture medium supplemented with DMSO as cryogenic preservative. Ampoules were prelabelled, autoclaved and heat-sealed (250 vials). They were checked for leaks and stored overnight at -70°C before storage in liquid nitrogen.

Cell Culture And Production Of Crude Harvest

Two vials from a master cell bank are thawed rapidly. Cells are pooled and inoculated in two T-flasks at 37° ± 1°C with an appropriate culture medium supplemented with 7.5 % dialysed foetal bovine (FBS) serum. When reaching confluence (passage 13), cells are collected by trypsinisation, pooled and expanded in 10 T-flasks as above. Confluent cells (passage 14) are trypsinised and expanded serially in 2 cell factory units (each 6000 cm²; passage 15), then in 10 cell factories (passage 16). The growth culture medium is supplemented with 7.5 % dialysed foetal bovine (FBS) serum and 1% MSX. When cells reach confluence, the growth culture medium is discarded and replaced by "production medium" containing only 1% dialysed foetal bovine serum and no MSX. Supernatant is collected every two

days (48 hrs-interval) for up to 32 days. The harvested culture fluids are clarified immediately through a 1.2-0.22 µm filter unit and kept at -20°C before purification.

Example 12: PURIFICATION OF HIV GP 120 (W61D CHO) FROM CELL CULTURE FLUID

All purification steps are performed in a cold room at 2-8°C. pH of buffers are adjusted at this temperature and are filtered on 0.2 µm filter. They are tested for pyrogen content (LAL assay). Optical density at 280 nm, pH and conductivity of column eluates are continuously monitored.

(i) Clarified Culture Fluid

The harvested clarified cell culture fluid (CCF) is filter-sterilized and Tris buffer, pH 8.0 is added to 30 mM final concentration. CCF is stored frozen at -20°C until purification.

(ii) <u>Hydrophobic Interaction Chromatography</u>

After thawing, ammonium sulphate is added to the clarified culture fluid up to 1 M. The solution is passed overnight on a TSK/TOYOPEARL-BUTYL 650 M (TOSOHAAS) column, equilibrated in 30 mM Tris buffer- pH 8.0 - 1 M ammonium sulphate. Under these conditions, the antigen binds to the gel matrix. The column is washed with a decreasing stepwise ammonium sulphate gradient. The antigen is eluted at 30 mM Tris buffer- pH 8.0 - 0.25 M ammonium sulphate.

(iii) Anion-exchange Chromatography

After reducing the conductivity of the solution between 5 and 6 mS/cm, the gP120 pool of fractions is loaded onto a Q-sepharose Fast Flow (Pharmacia) column, equilibrated in Tris-saline buffer - pH 8.0. The column is operated on a negative mode, i.e. gP120 does not bind to the gel, while most of the impurities are retained.

(iv) Concentration and diafiltration by ultrafiltration

In order to increase the protein concentration, the gP120 pool is loaded on a FILTRON membrane "Omega Screen Channel", with a 50 kDa cut-off. At the end of the concentration, the buffer is exchanged by diafiltration with 5 mM phosphate

buffer containing CaCl₂ 0.3 mM, pH 7.0. If further processing is not performed immediately, the gPl20 pool is stored frozen at -20°C. After thawing the solution is filtered onto a 0.2 μ M membrane in order to remove insoluble materiel.

(v) Chromatography on hydroxyapatite

The gP120 UF pool is loaded onto a macro-Prep Ceramic Hydroxyapatite, type II (Biorad) column equilibrated in 5 mM phosphate buffer + CaCl₂ 0.3 mM, pH 7.0. The column is washed with the same buffer. The antigen passes through the column and impurities bind to the column.

(vi) Cation exchange chromatography

The gP120 pool is loaded on a CM/TOYOPEARL-650 S (TOSOHAAS) column equilibrated in acetate buffer 20 mM, pH 5.0. The column is washed with the same buffer, then acetate 20 mM, pH 5.0 and NaCl 10 mM. The antigen is then cluted by the same buffer containing 80 mM NaCl.

(vii) <u>Ultrafiltration</u>

In order to augment the virus clearance capacity of the purification process, an additional ultrafiltration step is carried out. The gP120 pool is subjected to ultrafiltration onto a FILTRON membrane "Omega Screen Channel", cut-off 150 kDa. This pore-size membrane does not retain the antigen. After the process, the diluted antigen is concentrated on the same type of membrane (Filtron) but with a cut-off of 50 kDa.

(viii) Size exclusion Gel Chromatography

The gP120 pool is applied to a SUPERDEX 200 (PHARMACIA) column in order to exchange the buffer and to eliminate residual contaminants. The column is eluted with phosphate buffer saline (PBS).

(ix) Sterile filtration and storage

Fractions are sterilized by filtration on a 0.2 µM PVDF membrane (Millipore).

After sterile filtration, the purified bulk is stored frozen at -20°C up to formulation.

The purification scheme is summarized by the flow sheet below.

⇒ Level of purity of the purified bulk estimated by SDS-PAGE analysis (Silver staining / Coomassie Blue / Western Blotting) is ≥ 95%.

 \Rightarrow Production yield is around 2.5 mg/L CCF (according to Lowry assay) - Global purification yield is around 25% (according to Elisa assay)

⇒ Purified material is stable 1 week at 37°C (according to WB analysis)

Purification of gp120 from culture fluid

Mark √ indicate steps that are critical for virus removal.

CLARIFIED CULTURE FLUID

HYDROPHOBIC INTERACTION CHROMATOGRAPHY (BUTYL -TOYOPEARL 650 M)

ANION EXCHANGE CHROMATOGRAPHY (NEGATIVE MODE) (Q-SEPHAROSE)

50 KD ULTRAFILTRATION (CONCENTRATION AND BUFFER EXCHANGE)

(STORAGE -20°C)

.

HYDROXYAPATITE CHROMATOGRAPHY (NEGATIVE MODE) (MACROPREP CERAMIC HYDROXYAPATITE II)

CATION EXCHANGE CHROMATOGRAPHY (CM-TOYOPEARL 650 S)

150 KD ULTRAFILTRATION (OMEGA MEMBRANES / FILTRON)

50 KD ULTRAFILTRATION (CONCENTRATION)

SIZE EXCLUSION CHROMATOGRAPHY (SUPERDEX 200) STERILE FILTRATION

PURIFIED BULK STORAGE -20°C

Example 13: VACCINE PREPARATION

A vaccine prepared in accordance with the invention comprises the expression products of one or more DNA recombinants encoding an antigen. Furthermore, the formulations comprise a mixture of 3 de -O-acylated monophosphoryl lipid A 3D-MPL and QS21 in an oil/water emulsion or an oligonucleotide containing unmethylated CpG dinucleotide motifs and aluminium hydroxide as carrier.

3D-MPL: is a chemically detoxified form of the lipopolysaccharide (LPS) of the Gram-negative bacteria Salmonella minnesota.

Experiments performed at Smith Kline Beecham Biologicals have shown that 3D-MPL combined with various vehicles strongly enhances both the humoral immunity and a T_{HI} type of cellular immunity.

QS21: is a saponin purified from a crude extract of the bark of the Quillaja Saponaria Molina tree, which has a strong adjuvant activity: it induces both antigen-specific lymphoproliferation and CTLs to several antigens.

Experiments performed at Smith Kline Beecham Biologicals have demonstrated a clear synergistic effect of combinations of 3D-MPL and QS21 in the induction of both humoral and $T_{\rm HI}$ type cellular immune responses.

The oil/water emulsion is composed of 2 oils (a tocopherol and squalene), and of PBS containing Tween 80 as emulsifier. The emulsion comprises 5% squalene, 5%

tocopherol, 2% Tween 80 and has an average particle size of 180 nm (see WO 95/17210).

Experiments performed at Smith Kline Beecham Biologicals have proven that the adjunction of this O/W emulsion to 3D-MPL/QS21 further increases their immunostimulant properties.

Preparation of the oil/water emulsion (2 fold concentrate)

Tween 80 is dissolved in phosphate buffered saline (PBS) to give a 2% solution in the PBS. To provide 100ml two fold concentrate emulsion 5g of DL alpha tocopherol and 5ml of squalene are vortexed to mix thoroughly. 90ml of PBS/Tween solution is added and mixed thoroughly. The resulting emulsion is then passed through a syringe and finally microfluidised by using an M110S Microfluidies machine. The resulting oil droplets have a size of approximately 180 nm.

Preparation of oil in water formulation.

Antigens (100 μ g gp120, 20 μ g NefTat, and 20 μ g SIV Nef, alone or in combination) were diluted in 10 fold concentrated PBS pH 6.8 and H₂O before consecutive addition of the oil in water emulsion, 3D-MPL (50 μ g), QS21 (50 μ g) and 1 μ g/ml thiomersal as preservative at 5 min interval. The emulsion volume is equal to 50% of the total volume (250 μ l for a dose of 500 μ l).

All incubations were carried out at room temperature with agitation.

CpG oligonucleotide (CpG) is a synthetic unmethylated oligonucleotide containing one or several CpG sequence motifs. CpG is a very potent inducer of $T_{\rm HI}$ type immunity compared to the oil in water formulation that induces mainly a mixed $T_{\rm HI}/T_{\rm H2}$ response. CpG induces lower level of antibodies than the oil in water formulation and a good cell mediated immune response. CpG is expected to induce lower local reactogenicity.

Preparation of CpG oligonucleotide solution: CpG dry powder is dissolved in $\rm H_2O$ to give a solution of 5 mg/ml CpG.

Preparation of CpG formulation.

The 3 antigens were dialyzed against NaCl 150 mM to eliminate the phosphate ions that inhibit the adsorption of gp120 on aluminium hydroxide.

The antigens diluted in H_2O (100 µg gp120, 20 µg NefTat and 20 µg SIV Nef) were incubated with the CpG solution (500 µg CpG) for 30 min before adsorption on Al(OH)₃ to favor a potential interaction between the His tail of NefTat and Nef antigens and the oligonucleotide (stronger immunostimulatory effect of CpG described when bound to the antigen compared to free CpG). Then were consecutively added at 5 min interval Al(OH)₃ (500 µg), 10 fold concentrated NaCl and 1 µg/ml thiomersal as preservative.

All incubations were carried out at room temperature with agitation.

Example 14: IMMUNIZATION AND SHIV CHALLENGE EXPERIMENT IN RHESUS MONKEYS.

First Study

Groups of 4 rhesus monkeys were immunized intramuscularly at 0, 1 and 3 months with the following vaccine compositions:

```
Group 1:
            Adjuvant 2
                         + gp120
Group 2:
            Adjuvant 2
                         + gp120
                                      + NefTat
                                                   + SIV Nef
Group 3:
            Adjuvant 2
                                      + NefTat*
                                                   + SIV Nef
Group 4
            Adjuvant 6
                         + gp120
                                      + NefTat
                                                   + SIV Nef
Group 5
            Adjuvant 2
                                      + NefTat
                                                   + SIV Nef
Group 6
            Adjuvant 2
```

Adjuvant 2 comprises squalene/tocopherol/Tween 80/3D-MPL/QS21 and Adjuvant 6 comprises alum and CpG.

Tat* represents mutated Tat, in which Lys41→Ala and in RGD motif Arg78→Lys and Asp80→Glu (Virology 235: 48-64, 1997).

One month after the last immunization all animals were challenged with a pathogenic SHIV (strain 89.6p). From the week of challenge (wk16) blood samples were taken periodically at the indicated time points to determine the % of CD4-positive cells among peripheral blood mononuclear cells by FACS analysis (Figure 14) and the concentration of RNA viral genomes in the plasma by bDNA assay (Figure 15).

Results

All animals become infected after challenge with SHIV_{89.6p}-

CD4-positive cells decline after challenge in all animals of groups 1, 3, 5 and 6 except one animal in each of groups 1 and 6 (control group). All animals in group 2 exhibit a slight decrease in CD4-positive cells and recover to baseline levels over time. A similartrend is observed in group 4 animals (Figure 14).

Virus load data are almost the inverse of CD4 data. Virus load declines below the level of detection in 34 group 2 animals (and in the one control animal that maintains its CD4-positive cells), and the fourth animal shows only marginal virus load. Most of the other animals maintain a high or intermediate virus load (Figure 15).

Surprisingly, anti-Tat and anti-Nef antibody titres measured by ELISA were 2 to 3-fold higher in Group 3 (with mutated Tat) than in Group 5 (the equivalent Group with non-mutated Tat) throughout the course of the study.

At week 68 (56 weeks post challenge) all animals from the groups that had received the full antigen combination (groups 2 and 4) were still alive, while most of the animals in the other groupshad to be euthanized due to AIDS-like symptoms. The surviving animals per group were:

Group 1:	2/4
Group 2:	4/4
Group 3:	0/4
Group 4	4/4
Group 5	0/4
Group 6	1/4

Conclusions

The combination of gp120 and NefTat (in the presence of SIV Nef) prevents the loss of CD4-positive cells, reduces the virus load in animals infected with pathogenic SHIV_{89.6p}, and delays or prevents the development of AIDS-like disease symptoms, while gp120 or NefTat/SIV Nef alone do not protect from the pathologic consequences of the SHIV challenge.

The adjuvant 2 which is an oil in water emulsion comprising squalene, tocopherol and Tween 80, together with 3D-MPL and QS21 seems to have a stronger effect on the study endooints than the alum / CpG adjuvant.

Second study

A second rhesus monkey SHIV challenge study was conducted to confirm the efficacy of the candidate vaccine gp120/NefTat + adjuvant and to compare different Tat-based antigens. The study was conducted by a different laboratory.

The design of the study was as follows.

Groups of 6 rhesus monkeys were immunized at 0, 4 and 12 weeks with injections i.m. and challenged at week 16 with a standard dose of pathogenic SHIV_{89,6p}.

Group 1 is the reneat of Group 2 in the first study.

 Group 1:
 Adjuvant 2
 + gp120
 + NefTat
 + SIV Nef

 Group 2:
 Adjuvant 2
 + gp120
 + Tat (oxidised)

 Group 3:
 Adjuvant 2
 + gp120
 + Tat (reduced)

Group 4 Adjuvant 2

The follow-up/endpoints were again % CD4-positive cells, virus load by RT-PCR, morbidity and mortality

Results

All animals except one in group 2 become infected after challenge with SHIV89 60.

CD4-positive cells decline significantly after challenge in all animals of control group 4 and group 3, and in all but one animals of group 2. Only one animal in group 1 shows a marked decrease in CD4-positive cells. Unlike the animals from the first study, the monkeys in the second experiment display a stabilisation of CD4-positive cells at different levels one month after virus challenge (Figure 16). The stabilisation is generally lower than the initial % of CD4-positive cells, but will never lead to a complete loss of the cells. This may be indicative of a lower susceptibility to SHIV-induced disease in the monkey population that was used for the second study. Nonetheless, a beneficial effect of the gp120/NefTat/SIV Nef vaccine and the two gp120/Tat vaccines is demonstrable. The number of animals with a % of CD4-positive cells above 20 is 5 for the vaccinated animals, while none of the control animals from the adjuvant group remains above that level.

Analysis of RNA plasma virus loads confirms the relatively low susceptibility of the study animals (Figure 17). Only 2 of the 6 control animals maintain a high virus load, while the virus disappears from the plasma in the other animals. Thus, a vaccine effect is difficult to demonstrate for the virus load parameter.

Conclusions

Analysis of CD4-positive cells indicates that the vaccine gp120/NefTat + adjuvant (in the presence of SIV Nef) prevents the drop of CD4-positive cells in most vaccinated

49

animals This is a confirmation of the result obtained in the first SHIV study. Due to the lack of susceptibility of the study animals, the virus load parameter could not be used to demonstrate a vaccine effect. Taken together, the combination of gp120 and Tat and Nef HIV antigens provides protection against the pathologic consequences of HIV infection, as evidenced in a SHIV model.

The Tat alone antigens in combination with gp120 also provide some protection from the decline of CD4-positive cells. The effect is less pronounced than with the gp120/NefTat/SIV Nef antigen combination, but it demonstrates that gp120 and Tat are able to mediate some protective efficacy against SHIV-induced disease manifestations.

The second SHIV challenge study was performed with rhesus monkeys from a source completely unrelated to the source of animals from the first study. Both parameters, % of CD4-positive cells and plasma virus load, suggest that the animals in the second study were less susceptible to SHIV-induced disease, and that there was considerably greater variability among the animals. Nonetheless, a beneficial effect on the maintenance of CD4-positive cells of the gp120/NefTat/SIV Nef vaccine was seen with the experimental vaccine containing gp120/NefTat and SIV Nef. This indicates that the vaccine effect was not only repeated in a separate study, but furthermore demonstrated in an unrelated monkey nonulation.

CLAIMS

1. Use of a) an HIV Tat protein or polynucleotide; or

- b) an HIV Nef protein or polynucleotide; or
- c) an HIV Tat protein or polynucleotide linked to an HIV Nef protein or polynucleotide (Nef-Tat);

and an HIV gp120 protein or polynucleotide in the manufacture of a vaccine for the prophylactic or therapeutic immunisation of humans against HIV.

- Use as claimed in claim 1 wherein the Tat, Nef or Nef-Tat act in synergy with gp120 in the treatment or prevention of HIV.
- Use as claimed in claim 1 or claim 2 wherein the vaccine in use reduces the HIV viral load in HIV infected humans.
- Use as claimed in claims 1 or 2 wherein the vaccine in use results in a
 maintenance of CD4+ levels over those levels found in the absence of vaccination
 with HIV Tat, Nef or Nef-Tat and HIV gp120.
- Use as claimed in any one of claims 1 4 wherein the vaccine further comprises an antigen selected from the group consisting of; gag, rev, vif, vpr, vpu.
- Use as claimed in any one of claims 1 5 wherein the Tat protein is a mutated protein.
- Use as claimed in any one of claims 1 6 wherein the Tat, Nef or Nef-Tat
 protein is reduced.
- Use as claimed in any one of claims 1 7 wherein the Tat, Nef or Nef-Tat
 protein is carbamidomethylated.
- Use as claimed in any one of claims 1 6 wherein the Tat, Nef or Nef-Tat
 protein is oxidised.

10. Use as claimed in any one of claims 1-9 which additionally comprises an adjuvant.

- 11. Use as claimed in claim 10 wherein the adjuvant is a TH1 inducing adjuvant.
- Use as claimed in claim 10 or claim 11 wherein the adjuvant comprises monophosphoryl lipid A or a derivative thereof such as 3-de-O-acylated monophsphoryl lipid A.
- 13. Use as claimed in any one of claims 10 12 additionally comprising a saponin adjuvant.
- 14. Use as claimed in any one of claims 10 13 additionally comprising an oil in water emulsion.
- 15. Use as claimed in claim 10 or claim 11 wherein the adjuvant comprises CpG motif-containing oligonucleotides.
- 16. Use as claimed in claim 15 further comprising an aluminium salt.
- 17. Use of a) an HIV Tat protein or polynucleotide; or
 - b) an HIV Nef protein or polynucleotide; or
 - c) an HIV Tat protein or polynucleotide linked to an HIV Nef protein or polynucleotide;

and an HIV gp120 protein or polynucleotide in the manufacture of a vaccine suitable for a prime-boost delivery for the prophylactic or therapeutic immunisation of humans against HIV.

18. A method of immunising a human against HIV by administering to the human a vaccine comprising HIV Tat or HIV Nef or HIV NefTat in combination with HIV gp120 proteins or polynucleotides encoding them.

 A vaccine composition for human use which vaccine composition comprises HIV Tat or HIV Nef or HIV Nef-Tat in combination with HIV gp120 proteins or polynucleotides encoding them.

FIGURE 1

The DNA and amino acid sequences of Nef-His; Tat-His; Nef-Tat-His fusion and mutated Tat is illustrated.

Pichia-expressed constructs (plain constructs)

⇒ Nef - HIS

DNA sequence (Seq. ID. No. 8)

Protein sequence (Seq. ID. No. 9)

MGGKMSKSSVVGWPTVRERMRRAEPAADGVGAASRDLEKHGAITSSNTAATNAACAW LEAQEEEEVGF9VTPQVPLRPMTYKAAVDLSHFLKEKGGLEGLIHSQRRQDILDLWI YHTQGYF9DWQNYTPGGVRYPLTFGWCYKLVPVEPKVEEANKGENTSLLHPVSLH GMDDPEREVLEWRFDSRLAFHHYARZLHPEYFKNCTSGHHHHHI.

⇒ Tat - HIS

DNA sequence (Seq. ID. No. 10)

PCT/EP01/00944

WO 01/54719

Protein sequence (Seq. ID. No. 11)

MEPVDPRLEPWKHPGSOPKTACTNCYCKKCCFHCQVCFITKALGISYGRKKRRQRRR PPQGSQTHQVSLSKQPTSOSRGDPTGPKETSGHHHHHH.

⇒ <u>Nef - Tat - HIS</u>

DNA sequence (Seq. ID. No. 12)

ATGGGTGGCAAGTGGTCAAAAAGTAGTGTGGTTGGATGGCCTACTGTAAGGGAAAGA ATGAGACGAGCTGAGCCAGCAGCAGATGGGGTGGGAGCAGCATCTCGAGACCTGGAA AAACATGGAGCAATCACAAGTAGCAATACAGCAGCTACCAATGCTGCTTGTGCCTGG CTAGAAGCACAAGAGGAGGAGGAGGTGGGTTTTCCAGTCACACCTCAGGTACCTTTA AGACCAATGACTTACAAGGCAGCTGTAGATCTTAGCCACTTTTTAAAAGAAAAGGGG GGACTGGAAGGGCTAATTCACTCCCAACGAAGACAAGATATCCTTGATCTGTGGATC TACCACACACAAGGCTACTTCCCTGATTGGCAGAACTACACCAGGGCCAGGGGTC AGATATCCACTGACCTTTGGATGGTGCTACAAGCTAGTACCAGTTGAGCCAGATAAG GTAGAAGAGGCCAATAAAGGAGAGAACACCAGCTTGTTACACCCTGTGAGCCTGCAT GGAATGGATGACCCTGAGAGAGAGTGTTAGAGTGGAGGTTTGACAGCCGCCTAGCA TTTCATCACGTGGCCCGAGAGCTGCATCCGGAGTACTTCAAGAACTGCACTAGTGAG CCAGTAGATCCTAGACTAGAGCCCTGGAAGCATCCAGGAAGTCAGCCTAAAACTGCT CAAGGCAGTCAGACTCATCAAGTTTCTCTATCAAAGCAACCCACCTCCCAATCCCGA GGGGACCCGACAGGCCCGAAGGAAACTAGTGGCCACCATCACCATCACCATTAA

Protein sequence(Seq. ID. No. 13)

MGGKWSKSSVVGWPTVRERMRRAEPAADGVGAASRDLEKHGAITSSNTAATNAACAW LEAGEEEVGFPVTPQVPLRPMTYKAAVDLSHFLKEKGGLEGLIHSQRRQDILDLWI YHTQGYFPDWQNYTBGBGVRYPLIFGKCYKLVPVEPDKVEEANKGENTSLLHEVSLH GMDPEREVLEWRFDSRLAFHHVARELHPEYFKNCTSEPVDPALEPWKHPGSQPKTA CTNCYCKKCCFHCQVCFITKALGISYGRKKRRQRRPPQGSQTHQVSLSKQPTSQSR GDPTGPKETSGHHHHHH.

E.coli-expressed constructs (fusion constructs)

DNA sequence (Seq. ID. No. 14)

Nucleotides corresponding to the Prot D Fusion Partner are in bold. The Lipidation Signal Sequence is underlined. After processing, the cysteine coded by the TGT codon, indicated with a star, becomes the amino terminal residue which is then modified by covalently bound fatty acids.

 $\underline{ATGGATCCAAAAACTTTAGCCCTTTCTTTATTAGCAGCTGGCGTACTAGCAGGT$ TGT AGCAGCCATTCATCAAATATGGCGAATACCCAAATGAAATCAGACAAAATCATTATT GCTCACCGTGGTGCTAGCGGTTATTTACCAGAGCATACGTTAGAATCTAAAGCACTT GCTTTTGCACAACAGGCTGATTATTTAGAGCAAGATTTAGCAATGACTAAGGATGGT CGTTTAGTGGTTATTCACGATCACTTTTTAGATGGCTTGACTGATGTTGCGAAAAAA TTCCCACATCGTCATCGTAAAGATGGCCGTTACTATGTCATCGACTTTACCTTAAAA GAAATTCAAAGTTTAGAAATGACAGAAAACTTTGAAACCATGGGTGGCAAGTGGTCA AAAAGTAGTGTGGGTTGGATGGCCTACTGTAAGGGAAAGAATGAGACGAGCTGAGCCA GCAGCAGATGGGGTGGGAGCAGCATCTCGAGACCTGGAAAAACATGGAGCAATCACA AGTAGCAATACAGCAGCTACCAATGCTGCTTGTGCCTGGCTAGAAGCACAAGAGGAG GAGGAGGTGGGTTTTCCAGTCACACCTCAGGTACCTTTAAGACCAATGACTTACAAG GCAGCTGTAGATCTTAGCCACTTTTTAAAAGAAAAGGGGGGACTGGAAGGGCTAATT TTCCCTGATTGGCAGAACTACACCACGGGCCAGGGGTCAGATATCCACTGACCTTT GGATGGTGCTACAAGCTAGTACCAGTTGAGCCAGATAAGGTAGAAGAGGCCAATAAA GGAGAGAACACCAGCTTGTTACACCCTGTGAGCCTGCATGGAATGGATGACCCTGAG AGAGAAGTGTTAGAGTGGAGGTTTGACAGCCGCCTAGCATTTCATCACGTGGCCCGA GAGCTGCATCCGGAGTACTTCAAGAACTGCACTAGTGGCCACCATCACCATCACCAT

Protein sequence of the processed lipidated ProtD-Nef-HIS protein (Seq. ID. No. 15)

(Amino-acids corresponding to Prot D fusion partner are in bold)

CSSHSSMMANTQMKSDKIIIAHRGASGYLPEHTLESKALAFAQQADYLEQDLAMTKD
GRLVVIHDHFLDGLTDVAKKPPHRIRKDGRYYVIDFTLKETQSLEMTENFETMGGKM
SKSSVVGWPTVRERMRRAEPAADGVGAAGRDLEKHGAITSSNTAATNAACANLEAQE
EEZVGPPVTPQVPLRPMTYKAAVDLSHFLKEKGGLEGIIHSQRZQDILDLWIYHTQG
YFPDWQNYTPGPGVRYPLTFGWCYKLVPVEPDKVEEANKGENTSLLHPVSLHGMDDP
EREVLEWRFDSRLAFHHVARELHPEYFKNCTSGHHHHHH.

⇒ LipoD-Nef-Tat-HIS

DNA sequence (Seq. ID. No. 16)

Nucleotides corresponding to the Prot D Fusion Partner are in bold. The Lipidation Signal Sequence is underlined. After processing, the cysteine coded by the TGT codon, indicated with a star, becomes the amino terminal residue which is then modified by covalently bound fatty acids.

Protein sequence of the processed lipidated ProtD-NEF-TAT-HIS protein (Seq. ID. No. [7]

(Amino-acids corresponding to Prot D fusion partner are in bold)

CSSHSSMMANTQMKSDKIIIAHRGASGYLPEHTLESKALAFAQQADYLEQDLAMTKD
GRLVVHDHFLDGLTDVAKKFFHRHRKDGRYYVIDFTLKEIQSLEMTEHFETMGGKW
SKSSVVGWTTVRERMRRAEPAADGVGAASRDLEKHGAITSSNTAATNAACAWLEAQE
EEEVGFPVTPQVPDLAPMTYKAAVDLSHFLKEKGGLEGLIHGQRAQDILDLWIYHTQG
YFPDMGNYTPGPGVRYPLTFGWCYKLVPVEPDKVEEANKGENTSLLHPVSLERMDDP
EREVLEWRFDSALAFHHVARELHPEYFKNCTSEPVDRLEBWKHPGSQPKTACTNCY
CKKCGTHCQVCFITKALGISYGRKKRRQRRRPPQGSQTHQVSLSKQPTSQSRGDPTG
PKETSGHHHHHH.

⇒ ProtD-Nef -HIS

DNA sequence (Seq. ID. No. 18)

Nucleotides corresponding to the Prot D Fusion Partner are in bold.

ATGGATCCAAGCAGCCATTCATCAAATATGGCGAATACCCAAATGAAATCAGACAAA ATCATTATTGCTCACCGTGGTGCTAGCGGTTATTTACCAGAGCATACGTTAGAATCT AAAGCACTTGCGTTTGCACAACAGGCTGATTATTTAGAGCAAGATTTAGCAATGACT AAGGATGGTCGTTTAGTGGTTATTCACGATCACTTTTTAGATGGCTTGACTGATGTT GCGAAAAAATTCCCACATCGTCATCGTAAAGATGGCCGTTACTATGTCATCGACTTT ACCTTAAAAGAAATTCAAAGTTTAGAAATGACAGAAAACTTTGAAACCATGGGTGGC AAGTGGTCAAAAAGTAGTGTGGTTGGATGGCCTACTGTAAGGGAAAGAATGAGACGA GCTGAGCCAGCAGCAGATGGGGTGGGAGCAGCATCTCGAGACCTGGAAAAACATGGA GCAATCACAAGTAGCAATACAGCAGCTACCAATGCTGCTTGTGCCTGGCTAGAAGCA CAAGAGGAGGAGGAGGTGGGTTTTCCAGTCACACCTCAGGTACCTTTAAGACCAATG ACTTACAAGGCAGCTGTAGATCTTAGCCACTTTTTAAAAGAAAAGGGGGGACTGGAA GGGCTAATTCACTCCCAACGAAGACAAGATATCCTTGATCTGTGGATCTACCACACA CAAGGCTACTTCCCTGATTGGCAGAACTACACACCAGGGCCCAGGGGTCAGATATCCA CTGACCTTTGGATGGTGCTACAAGCTAGTACCAGTTGAGCCAGATAAGGTAGAAGAG GCCAATAAAGGAGAGAACACCAGCTTGTTACACCCTGTGAGCCTGCATGGAATGGAT GACCCTGAGAGAGAGTGTTAGAGTGGAGGTTTGACAGCCGCCTAGCATTTCATCAC GTGGCCCGAGAGCTGCATCCGGAGTACTTCAAGAACTGCACTAGTGGCCACCATCAC CATCACCATTAA

Protein sequence (Seq. ID. No. 19)

(Amino-acids corresponding to Prot D fusion partner are in bold)

MDPSSHSSNMANTQMKSDKIIIAHRGASGYLPEHTLESKALAFAQQADYL EQDLAMTKDGRLVVHDIFFLDGLTDVAKKFPHRHRKDGRYYVIDFTLK EIQSLEMTENFETMGGKWSKSSVVGWPTVRERMRRAEPAADGVGAASRDL EKHGAITSSNTAATNAACAWLEAQEEEEVGFPVTQVPLRPMTYKAAVDLSH FLKEKGGLEGLHSQRRQDILDLWIYHTQGYFPDWQNYTPGFGVKYPLTFGW CYKLVPVEPDKVEEANKGENTSLLHPVSLHGMDDPEREVLEWRFDSRLAFH HVARELHPEVFKNCTSGHIHHHHH.

⇒ ProtD-Nef -Tat-HIS

DNA sequence (Seq. ID. No. 20)

Nucleotides corresponding to the Prot D Fusion Partner are in bold.

ATGGATCCAAGCAGCCATTCATCAAATATGGCGAATACCCAAATGAAATCAGACAAA ATCATTATTGCTCACCGTGGTGCTAGCGGTTATTTACCAGAGCATACGTTAGAATCT AAAGCACTTGCGTTTGCACAACAGGCTGATTATTTAGAGCAAGATTTAGCAATGACT AAGGATGGTCGTTTAGTGGTTATTCACGATCACTTTTTAGATGGCTTGACTGATGTT GCGAAAAAATTCCCACATCGTCATCGTAAAGATGGCCGTTACTATGTCATCGACTTT ${\tt ACCTTAAAAGAAATTCAAAGTTTAGAAATGACAGAAAACTTTGAAACCATGGGTGGC}$ AAGTGGTCAAAAAGTAGTGTGGTTGGATGGCCTACTGTAAGGGAAAGAATGAGACGA GCTGAGCCAGCAGATGGGGTGGGAGCAGCATCTCGAGACCTGGAAAAACATGGA GCAATCACAAGTAGCAATACAGCAGCTACCAATGCTGCTTGTGCCTGGCTAGAAGCA CAAGAGGAGGAGGAGGTGGGTTTTCCAGTCACACCTCAGGTACCTTTAAGACCAATG ACTTACAAGGCAGCTGTAGATCTTAGCCACTTTTTAAAAGAAAAGGGGGGACTGGAA GGGCTAATTCACTCCCAACGAAGACAAGATATCCTTGATCTGTGGATCTACCACACA CAAGGCTACTTCCCTGATTGGCAGAACTACACCAGGGCCAGGGGTCAGATATCCA CTGACCTTTGGATGGTGCTACAAGCTAGTACCAGTTGAGCCAGATAAGGTAGAAGAG GCCAATAAAGGAGAGAACACCAGCTTGTTACACCCTGTGAGCCTGCATGGAATGGAT GACCCTGAGAGAGAAGTGTTAGAGTGGAGGTTTGACAGCCGCCTAGCATTTCATCAC GTGGCCCGAGAGCTGCATCCGGAGTACTTCAAGAACTGCACTAGTGAGCCAGTAGAT CCTAGACTAGAGCCCTGGAAGCATCCAGGAAGTCAGCCTAAAACTGCTTGTACCAAT GGCATCTCCTATGGCAGGAAGAAGCGGAGACAGCGAAGACCTCCTCAAGGCAGT CAGACTCATCAAGTTTCTCTATCAAAGCAACCCACCTCCCAATCCCGAGGGGACCCG ACAGGCCCGAAGGAAACTAGTGGCCACCATCACCATCACCATTAA

Protein sequence (Seq. ID. No. 21)

(Amino-acids corresponding to Prot D fusion partner are in bold)

MDFSSHSSMANTQMKSDKIIIAHRGASGYLPEHTLESKALAFAQQADYLEQDLAMT KDGRLVVIHDHFLDGLTDVAKKFPHRHRKDGRYYVIDFTLKEIGSLEMTENFETMGG KWSKSSVVGWPTVREMRRAEPAADGVGAASRDLEKHGAITSSNTAATNAACAWLEA GEEEVGFPVTPQVPLRPMTYKAAVDLSHFLKEKGGLEGLHSGRRGDILDLWIYHT GGFPDMONYTPOFGVRYPLTFGWCYKLVPVEPDKVEEANKGENTSLHPVSLHODD PPEREVLEWRFDSRAFHHVARELHPSYFKNCTSEPVDPRLEPWKHPGSQPKTACTN CYCKKCCFHCQVCFITKALGISYGRKKRRQRRPPOGSQTHQVSLSKQPTSQSRGDP TGFKETSGHWHHH

⇒ Tat-MUTANT-HIS

DNA sequence (Seq. ID. No. 22)

PCT/EP01/00944 WO 01/54719

ATGGAGCCAGTAGATCCTAGACTAGAGCCCTGGAAGCATC	40
CAGGAAGTCAGCCTAAAACTGCTTGTACCAATTGCTATTG	80
TAAAAAGTGTTGCTTTCATTGCCAAGTTTGTTTCATAACA GCTGCCTTAGGCATCTCCTATGCAGGAAGAAGCGGAGAC	120
AGCGACGAAGACCTCCTCAAGGCAGTCAGACTCATCAAGT	160
TTCTCTATCAAAGCAACCCACCTCCCAATCCAAAGGGGAG	240
CCGACAGGCCCGAAGGAAACTAGTGGCCACCATCACCATC	280
ACCATTAA	288

<u>Protein sequence(Seq. ID. No. 23)</u>
Mutated amino-acids in Tat sequences are in bold.

MEPVDPRLEPWKHPGSQPKTACTNCYCKKCCFHCQVCFIT AALGISYGRKKRRQRRRPPQGSQTHQVSLSKQPTSQSKGE	40
PTGPKETSGHHHHHH.	9:

⇒Nef-Tat-Mutant-HIS

DNA sequence(Seq. ID. No. 24)


ATGGGTGGCAAGTGGTCAAAAAGTAGTGTGGTTGGATGGC	4 (
CTACTGTAAGGGAAAGAATGAGACGAGCTGAGCCAGCAGC	**
AGATGGGGTGGGAGCAGCATCTCGAGACCTGGAAAAACAT	
GGAGCAATCACAAGTAGCAATACAGCAGCTACCAATGCTG	120
CTTGTGCCTGGCTAGAAGCACAAGAGGAGGAGGAGGTGGG	.160
TTTTCCAGTCACACCTCAGGTACCTTTAAGACCAATGACT	
TACAAGGCAGCTGTAGATCTTAGCCACTTTTAAAAGAAA	240
AGGGGGACTGGAAGGCTAATTCACTCCCAACGAAGACA	280
AGATATCCTTGATCTCTCCCAACGAAGACA	320
AGATATCCTTGATCTGTGGATCTACCACACACACAAGGCTAC	360
TTCCCTGATTGGCAGAACTACACACCAGGGCCAGGGGTCA	400
GATATCCACTGACCTTTGGATGGTGCTACAAGCTAGTACC	440
AGTTGAGCCAGATAAGGTAGAAGAGGCCAATAAAGGAGAG	480
AACACCAGCTTGTTACACCCTGTGAGCCTGCATGGAATGG	520
ATGACCCTGAGAGAGAGTGTTAGAGTGGAGGTTTGACAG	560
CCGCCTAGCATTTCATCACGTGGCCCGAGAGCTGCATCCG	600
GAGTACTTCAAGAACTGCACTAGTGAGCCAGTAGATCCTA	640
GACTAGAGCCCTGGAAGCATCCAGGAAGTCAGCCTAAAAC	680
IGC ITGTACCAATTGCTATTGTAAAAAGTGTTGCTTCAT	720
1GCCAAGTTTGTTTCATAACAGCTGCCTTAGGCATCTCCT	760
ALGGCAGGAAGAGCGGAGACACCTCCTCA	800
AGGCAGTCAGACTCATCAAGTTTCTCTATCAAACCAACCA	
ACCTCCCAATCCAAAGGGGAGCCGACAGGCCCGAAGGAAA	840
CTAGTGGCCACCATCACCATCACCATTAA	880
- Culting	909

<u>Protein sequence (Seq. ID. No. 25)</u> Mutated amino-acids in Tat sequence are in bold.

MGGKWSKSSVVGWPTVRERMRRAEPAADGVGAASRDLEK GAITSSNTAATNAACA	
GAITSSNTAATNA CAN BAGARAEPAADGVGAASRDLEKI	I 4
GAITSSNTAATNAACAWLEAQEEEEVGFPVTPQVPLRPMI YKAAVDLSHFLEEVOO	. 8
YKAAVDLSHFLKEKGGLEGLIHSQRRQDILDLWIYHTQGY FPDWQNYTPGPQNPYDY	12
FPDWQNYTPGPGVRYPLTFGWCYKLVPVEPDKVEEANKGE NTSLLHPVSLHGWDDDDD	160
NTSLLHPVSLHGMDDPEREVLEWRFDSRLAFHHVARELHP EYFKNCTSEPVDBBLEDV	200
THE PWKHPCSODVER ACTION	
TO THE TAKKER OF THE PROPERTY	280
SQSKGEPTGPKETSGHHHHHH.	200

Figure 2

Map of pRIT14597 integrative vector



MCS POLYLINKER nef gene inserted between NcoI and SpeI sites.

ASU II Noo I Spe I Eco RI
TTCGAA.ACC.ATGGCCGCGGGCTAGTGGC.CAC.CAT.CAC.CAT.CAC.CAT.TAA.CGGAATTC
Thr.Ser.Gly. His. His. His. His. His. His. His.

The amino acid sequence of Figure 2-relates to Seq. ID no. 27 and the nucleic acid sequence of Figure 3 relates to Seq. ID. No. 26.

Figure 3: SDS-PAGE: Nef-Tat-his fusion protein



- 1: MW (175/83/62,5/47,5/32,5/25/16,5/6,5 kDa
- 2: TNH/23 SP eluate (250 ng)
- 3: TNH/23 Purified bulk (250 ng) 4: TNH/22 Purified bulk (250 ng)
- 5: MW (175/83/62,5/47,5/32,5/25/16,5/6,5 kDa
- 6: TNH/23 SP eluate (400 ng) 7: TNH/23 Purified bulk (400 ng)
- 8: TNH/22 Purified bulk (400 ng)








Figure 4 .: SDS-PAGE: Nef-Tat-his fusion protein



Coomassie blue G250

- 1: MW (175/83/62,5/47,5/32,5/25/16,5/6,5 kDa)
- 2: TNH/23 SP eluate (4 μg)
- 3: TNH/23 Superdex200 eluate (4 µg)
- 4: TNH/23 Purified bulk (4 μg)
- 5: TNH/22 Purified bulk (4 µg)
- 6: TNH/23 Purified bulk (4 µg) / non reducing conditions
- 7: TNH/22 Purified bulk (4 µg) / non reducing conditions

Figure 6: SDS-PAGE ANALYSIS – reducing conditions (14% polyacrylamide precasted gels - Novex) See example 5



Silver staining

Western blot a Tat

- 1: MW (175/83/62/47,5/32,5/25/16,5/6,5 kDa)
- 2: Purified bulk
- 3: Purified bulk

Figure 7 (relating to Example 6): SDS-PAGE ANALYSIS: (4-20% polyacrylamide precasted gels - Novex)

1 2 3 4

5 6 3

1 2 3 4


5 6 7

Coomassie blue G250

Western blot anti Tat

- 1: MW (175/83/62,5/47,5/32,5/25/16,5/6,5 kDa)
- 2: Purified bulk (reducing conditions)
- 3: Purified bulk (reducing conditions)
- 4: Purified bulk (reducing conditions)
- 5: Purified bulk (non reducing conditions)
- 6: Purified bulk (non reducing conditions)
- 7: Purified bulk (non reducing conditions)

Figure 8 (relating to Example 7): SDS-PAGE ANALYSIS: (4-20% pc lyacrylamide precasted gels - Novex)



Coomassie blue G250

Western blot anti Tat

- 1: MW (175/83/62,5/47,5/32,5/25/16,5/6,5 kDa)
- 2: Purified bulk (reducing conditions)
- 3: Purified bulk (non reducing conditions)

FIGURE 9: SDS-PAGE ANALYSIS - REDUCING CONDITIONS

(14% polyacrylamide precasted gels - Novex) see Example 8

1 2 3


Coomassie blue R250

1 2 3

Silver staining

Figure 10: SDS-PAGE ANALYSIS - REDUCING CONDITIONS

(14% polyacrylamide precasted gels - Novex) See Example 9



Coomassie blue G250

Silver staining


W. Blot a Nef

1: MW (175/83/62,5/47,5/32,5/25/16,5/6,5 kDa)

2: Purified bulk

Figure 11

Map of pRIT14908 integrative vector



MCS POLYLINKER: NEF gene inserted between NcoI and SpeI sites.

 Assu II
 Noo 1
 Spe I
 Eco RI

 TTCGAA.A
 CC.ATGGCCCCCGG
 ACTAGT. GGC.CAC.CAT.CAC.CAT.CAC.CAT.TAA.COC
 GAATTC

 Thr .Ser . Gly. His . His

Figure 12


Sequences of Pichia-expressed SIV-NEF-His protein

DNA SEQUENCE:

PROTEIN SEQUENCE:

MGGAISMRRSRPSGDLRQRLLRARGETYGRLLGEVEDGYSQSPGGLDKGL	50
SSLSCEGQKYNQGQYMNTPWRNPAEEREKLAYRKQNMDDIDEEDDDLVGV	100
SVRPKVPLRTMSYKLAIDMSHFIKEKGGLEGIYYSARRHRILDIYLEKEE	150
GIIPDWQDYTSGPGIRYPKTFGWLWKLVPVNVSDEAQEDEEHYLMHPAQT	200
SQWDDPWGEVLAWKFDPTLAYTYEAYVRYPEEFGSKSGLSEEEVRRRLTA	250
RGLLNMADKKETRTSGHHHHHH.	272

Figure 13
Coomassie Blue Stained SDS-PAGE of recombinant Pichia pastoris SIV/NEF expressing strains



lane 1: P- Y1752 strain

lane 2: S- " "


lane 3: P- Y1772 strain


lane 4: S- " " "


lane 7: P- GS115 strain (negative control)

lane 8: S- "


Figure 14. Monkey study 1. Analysis of CD4-positive cells among PBMCs before and after challenge with SHIV


















Figure 15. Monkey study 1. Analysis of SHIV plasma virus load after challenge with SHIV





5.00 to 10.00 to 10.0










Figure 16. Monkey study 2. Analysis of CD4-positive cells among PBMCs before and after challenge with SHIV





Figure 17. Monkey study 2. Analysis of SHIV plasma virus load after challenge with SHIV



SECUENCE LISTING

<pre></pre>	<110>	SmithKline Beecham Biologicals S.A.	
<pre><130> B45209</pre>	<120>	> Novel Use	
<pre><160> 31</pre>			
<pre><160> 31</pre>			
<pre><170> FastSEQ for Windows Version 3.0 <210> 1</pre>	<130>	> B45209	
<pre><170> FastSEQ for Windows Version 3.0 <210> 1</pre>	<160>	31	
<pre> <210> 1</pre>		- 	
<pre><211> 28</pre>	<170>	> FastSEQ for Windows Version 3.0	
<pre><211> 28</pre>			
<pre><212> DNA <213> Artificial Sequence <220> <2223> primer <400> 1 atcgtccate nggtnggcna agntggnt 28 <210> 2</pre>			
<pre><213> Artificial Sequence</pre>			
<pre> <220></pre>			
<pre><223> primer <400> 1</pre>			
<pre><400> 1 atcgtccatg nggtngcna agntggnt</pre>			
atcgtccatg nggtnggcna agntggnt 286	<223:	> primer	
atcgtccatg nggtnggcna agntggnt 286	<400:	. 1	
<pre><210> 2</pre>			28
<pre><211> 23</pre>			
<pre><212> DNA <213> Artificial Sequence <220> <223> primer <400> 2 cggctactag tgcagttctt gaa</pre>			
<pre><213> Artificial Sequence</pre>			
<pre> <220> <223> primer <400> 2 cggctactag tgcagttctt gaa</pre>			
<pre><223> primer <400> 2 cggctactag tgcagtctt gaa</pre>	(213	> Artificial Sequence	
<pre><400> 2 cggctactag tgcagtctt gaa</pre>	<220:	>	
cggctactag tgcagttctt gaa 23 <210-3 <211-29 <212- DNA <213- Artificial Sequence <220- <223- primer <400-3 atcgtactag tngagnocan gtangatno <210-4 <211-24 <211- DNA <113- Artificial Sequence <220- <223- primer <400-4 <211- 24 <212- DNA <213- Artificial Sequence <220- <223- primer <400-4 cggctactag tttccttcgg gcct <210-5 <211-23 <212- DNA	<223:	> primer	
cggctactag tgcagttctt gaa 23 <210-3 <211-29 <212- DNA <213- Artificial Sequence <220- <223- primer <400-3 atcgtactag tngagnocan gtangatno <210-4 <211-24 <211- DNA <113- Artificial Sequence <220- <223- primer <400-4 <211- 24 <212- DNA <213- Artificial Sequence <220- <223- primer <400-4 cggctactag tttccttcgg gcct <210-5 <211-23 <212- DNA			
<210> 3 <211> 29 <212> DNA <213> Artificial Sequence <220> <223> primer <400> 3 atogtactag tngagnocan gtangatno <210> 4 <211> 24 <212> DNA <213> Artificial Sequence <220> <223> primer <210> 4 <212> DNA <213> Artificial Sequence <220> <223> primer <210> 4 <212> DNA <213> Artificial Sequence <220> <221> primer <210> 4 <212> DNA <212> DNA <213> DNA <213> DNA <213> DNA <214 <214 <215 DNA <216 DNA <217 DNA <218 DNA <228 D			23
<pre><211> 29</pre>	-33		
<pre><212> DNA <211> Artificial Sequence <220> <223> primer <400> 3 atcgtactag tngagnocan gtangatno</pre>			
<pre></pre>			
<220> <223> primer <400			
<pre> <223> primer <400> 3 atogtactag tngagnocan gtangatno</pre>	<213	> Artificial sequence	
<pre><400> 3 atcgtactag tngagnccan gtangatnc</pre>	<220	>	
ategtactag tngagnecan gtangatne 23 <210	<223	> primer	
ategtactag tngagnecan gtangatne 23 <210			
<pre><210> 4</pre>			29
<pre><211> 24 <212> DNA <213> Artificial Sequence <220> <223> primer <400> 4 cggctactag tttccttcgg gcct</pre>	accycaccag	engagneean geangaene	
<pre><212> DNA <213> Artificial Sequence <220> <223> primer <400> 4</pre>	<210	> 4	
<pre><213> Artificial Sequence <220> <223> primer <400> 4 cggctactag tttccttcgg gcct</pre>			
<220> <223> primer <400> 4 <ggctactag <210="" geet="" tttecttegg=""> 5 <211> 23 <212> DNA</ggctactag>			
<223> primer <400> 4 cggctactag tttccttcgg gcct <210> 5 <211> 23 <212> DNA	<213	> Artificial Sequence	
<223> primer <400> 4 cggctactag tttccttcgg gcct <210> 5 <211> 23 <212> DNA	-220		
<0105 4 cggctactag tttcettcgg gcct 24 <2105 5 <2115 23 <2125 DNA			
cggctactag tttccttcgg gcct 24 <210> 5 <211> 23 <212> DNA			
<210> 5 <211> 23 <212> DNA			
<211> 23 <212> DNA	cggctactag	f tttccttcgg gcct	24
<211> 23 <212> DNA	<210)	
<212> DNA			
<213> Artificial Sequence	<213	3> Artificial Sequence	
	<211 <212	L> 23 2> DNA	

<223> primer	
<400> 5	
atcgtccatg gagccagtag atc	23
<210> 6	
<211> 24	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> primer	
<400> 6	
atcgtccatg ggtggagcta tttt	24
<210> 7	
<211> 23	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> primer	
<400> 7	
cggctactag tgcgagtttc ctt	23
<210> 8	
<211> 648	
<212> DNA	
<213> human	
<400> 8	
<400> 8 atgggtggca agtggtcaaa aagtagtgtg gttggatggc ctactgta	ag ggaaagaatg 60
agacgagctg agccagcagc agatggggtg ggagcagcat ctcgagac	
ggagcaatca caagtagcaa tacagcagct accaatgctg cttgtgcc	
caagaggagg aggaggtggg tittccagtc accastgctg tacctta	
tacaaggcag ctgtagatct tagccacttt ttaaaagaaa agggggga	
attcactccc aacgaagaca agatatcctt gatctgtgga tctaccac	
ttccctgatt ggcagaacta cacaccaggg ccaggggtca gatatcca	
tggtgctaca agctagtacc agttgagcca gataaggtag aagaggcc	
aacaccagct tgttacaccc tgtgagcctg catggaatgg atgaccct	
ttagagtgga ggtttgacag ccgcctagca tttcatcacg tggcccga	
gagtactica agaactgcac tagtggccac catcaccatc accattaa	. 040
<210> 9	
<211> 215	
<212> PRT	
<213> human	
<400> 9	
Met Gly Gly Lys Trp Ser Lys Ser Ser Val Val Gly Trp	Pro Thr Val
1 5 10	15
Arg Glu Arg Met Arg Arg Ala Glu Pro Ala Ala Asp Gly	Val Gly Ala
20 25	30
Ala Ser Arg Asp Leu Glu Lys His Gly Ala Ile Thr Ser	Ser Asn Thr
35 40 45	
Ala Ala Thr Asn Ala Ala Cys Ala Trp Leu Glu Ala Gln 50 55 60	Glu Glu Glu
	Des Mon Thy
Glu Val Gly Phe Pro Val Thr Pro Gln Val Pro Leu Arg	Pro Met Ini
Tyr Lys Ala Ala Val Asp Leu Ser His Phe Leu Lys Glu	
85 90	95
Leu Glu Gly Leu Ile His Ser Gln Arg Arg Gln Asp Ile	Leu Asp Leu

O 01/	5471	9													rcı,	EI GI/GO
_		_	100				_	105	_	_	_		110	_	ml	
Trp	TTE	115	HIS	Thr	GIn	GI-7	120	Phe	Pro	Asp	Trp	125	Asn	Tyr	Int	
Bro	GLV		GLV	Va l	2	The c		Lan	The	Dho	C111		Cve	Tyr	Larg	
110	130	FLO	GIY	***	nra	133	FLU	Deu	****	riie	140	rrp	Cys	-,-	2,0	
Leu		Pro	Val	Glu	Pro		Lvs	Val	Glu	Glu		Asn	Lvs	Gly	Glu	
145					150	,				155			•		160	
Asn	Thr	Ser	Leu	Leu	His	Pro	√a1	Ser	Leu	His	Gly	Met	Asp	Asp	Pro	
				165					170					175		
Glu	Arg	Glu		Leu	Glu	Trp	Arg		Asp	Ser	Arg	Leu		Phe	His	
			180					185					190			
His	Val		Arg	Glu	Leu	His		Glu	Tyr	Phe	Lys		Сув	Thr	Ser	
63	***	195					200					205				
GIY	210	His	HIS	HIS	HIS	215										
	210					215										
	٠.	210>	10													
		211>														
		212>														
		213>		an												
		+00>														
															aaact	60
															taaca	120
															ctcaa	180
														ccga	gggac	240
cega	cag	gee o	cgaa	ggaa	ac ta	agtg	gcca	c cai	cac	catc	acca	attaa	a .			288
	-	210>	11													
		211>														
		212>														
		213>		an												
	<	\$00>	11													
	Glu	Pro	Val	Asp	Pro	Arg	Leu	Glu	Pro	Trp	Lys	His	Pro	Gly	Ser	
1				5					10					15		
Gln	Pro	Lys		Ala	Cys	Thr	Asn		Tyr	Cys	Lys	Lys		Cys	Phe	
*** -	۵		20	_	_,		-	25					30			
nıs	Cys	35	vaı	Cys	Pne	TTE	40	Lys	ATA	Leu	GIY	45	ser	Tyr	GIA	
Ave	Tara		3	7	C1 -	A		7	200	nue	~1 m			Gln	Thr	
nig	50	шуь	ALG	Arg	GIII	55	ALG	ALG	PIO	PLO	60	GIY	261	GIII	1111	
His		Val	Ser	Leu	Ser		Gln	Pro	Thr	Ser		Ser	Ara	Gly	Asp	
65					70	-,-				75					80	
Pro	Thr	Gly	Pro	Lys	Glu	Thr	Ser	Glv	His		His	His	His	His		
				85				-	90					95		
		210>														
		211>														
		212>														
	<	213>	hum	an												
		400>	12													
atm				at co		agt c	atat	~ ~=	taas		ct :	tat:			gaate	60
															igaatg laacat	120
															gaagca	180
															tgact	240
															ggcta	300
															gctac	360
															ttgga	420
															gagag	480
aac	acca	gct	tgtt	acac	cc t	gtga	gcct	g ca	tgga	atgg	atga	accel	tga -	gaga	gaagtg	540
tta	gagt	gga	ggtt	tgac	ag c	cgcc	tagc	a tt	tcat	cacg	tgg	cccga	aga -	gctg	catccg	600
gag	tact	tca .	agaa	ctgc	ac t	agtg	agcc	a qt	agat	ccta	qac	agag	CC .	ctgg	agcat	660

ccaggaagtc goctaaaac tgottgtacc aattgctatt gtaaaaagtg ttgctttoat tgccaagtt gttcataac aaaagcctta ggcatctect atggcaggaa gaagcggaga caggacgaa gacctcotca aggcagtcag actcatcaag tttotctatc aaagcaaccc acctccaat cccgaggga ccgacaggc ccgaaggaa ctagtggcca ccatcaccat caccattaa

<210> 13 <211> 302 <212> PRT <213> human

<400× 13 Met Gly Gly Lys Trp Ser Lys Ser Ser Val Val Gly Trp Pro Thr Val 1 10 Arg Glu Arg Met Arg Arg Ala Glu Pro Ala Ala Asp Gly Val Gly Ala 25 30 Ala Ser Arg Asp Leu Glu Lys His Gly Ala Ile Thr Ser Ser Asn Thr Ala Ala Thr Asn Ala Ala Cys Ala Trp Leu Glu Ala Gln Glu Glu Glu 55 Glu Val Gly Phe Pro Val Thr Pro Gln Val Pro Leu Arg Pro Met Thr 70 75 Tyr Lys Ala Ala Val Asp Leu Ser His Phe Leu Lys Glu Lys Gly Gly Leu Glu Gly Leu Ile His Ser Gln Arg Arg Gln Asp Ile Leu Asp Leu 100 105 Trp Ile Tyr His Thr Gln Gly Tyr Phe Pro Asp Trp Gln Asn Tyr Thr 115 125 120 Pro Gly Pro Gly Val Arg Tyr Pro Leu Thr Phe Gly Trp Cys Tyr Lys 130 135 140 Leu Val Pro Val Glu Pro Asp Lys Val Glu Glu Ala Asn Lys Gly Glu 145 150 155 160 Asn Thr Ser Leu Leu His Pro Val Ser Leu His Gly Met Asp Asp Pro 165 170 Glu Arg Glu Val Leu Glu Trp Arg Phe Asp Ser Arg Leu Ala Phe His 180 185 190 His Val Ala Arg Glu Leu His Pro Glu Tyr Phe Lys Asn Cys Thr Ser 195 200 205 Glu Pro Val Asp Pro Arg Leu Glu Pro Trp Lys His Pro Gly Ser Gln 215 210 220 Pro Lys Thr Ala Cys Thr Asn Cys Tyr Cys Lys Lys Cys Cys Phe His 230 235 Cys Gln Val Cys Phe Ile Thr Lys Ala Leu Gly Ile Ser Tyr Gly Arg 245 250 255 Lys Lys Arg Arg Gln Arg Arg Pro Pro Gln Gly Ser Gln Thr His 265 270 Gln Val Ser Leu Ser Lys Gln Pro Thr Ser Gln Ser Arg Gly Asp Pro 275 280 Thr Gly Pro Lys Glu Thr Ser Gly His His His His His His 295

<210> 14

<211> 1029 <212> DNA

<212> DNA <213> human

<400> 14

atggatccaa aaacttago cottoctta ttagoagotg gogtactago aggstgtago agccattoat caaatatgo gaatacocaa atgaaatoag acaaaatoat tattggtcac oggtgcta goggtatta accaagotat togtagaat ctaaagotat tgotttgca caacaggotg attattaga gcaagatta goaatgacta aggatggtog ttagtggtog acaagotgtog attactaga goagotgtog attactagotgac actitagaggot attacagota actititaga gcagtiagot gattagotgac goggtagotg aggatgagotga attacagotaa actititagaa gcagtagotga ttagotgaca aagaaattca aagttagaa atgaaagaa actitagaac actitagaac actitagotgac acaattagotgacaagotgacago

cctattgtaa gggaaagaat gagacagact gagccagcag cagatggggt gggagcagca Lctcagagace tggaaaaca tgagacata caagatgaa gtttacagace gcttgtgct ggctagaagc acaagaggag gaggaggtgg gttttccagt cacactcag gcttgtgct ggctagaagc acaagaggag gaggaggtgg gttttccagt cacactcag gaggaggac tggaaggct acttcactcc caacgaagac aagatatcct tgattgtgg actaccaca cacaaggcta cttcactcct acagcagagac aagatatcct tgattgtgg actaccacac cacaaggcta cttcactctga tggcagaaact acacaccag gccagggtc gagatatccac tgaccttgg atggtgctac aagatataca cgttgagacc agataaggta gaagagcca ataaaggaag aacaccagc ttgtacacc cgtgagcct gcatggaatg gatgaccctp agaagagaagt gttagagtgg aggttgaac gccctagc attcatcac gtggccogag agctgcatcc ggagtactc aagaactgca ctagtggcca ccatcaccat accactaa

540

<210> 15 <211> 324 <212> PRT <213> human

<400> 15

Cys Ser Ser His Ser Ser Asn Met Ala Asn Thr Gln Met Lys Ser Asp Lys Ile Ile Ile Ala His Arg Gly Ala Ser Gly Tyr Leu Pro Glu His 25 Thr Leu Glu Ser Lys Ala Leu Ala Phe Ala Gln Gln Ala Asp Tyr Leu Glu Gln Asp Leu Ala Met Thr Lys Asp Gly Arg Leu Val Val Ile His 55 Asp His Phe Leu Asp Gly Leu Thr Asp Val Ala Lys Lys Phe Pro His 70 Arg His Arg Lys Asp Gly Arg Tyr Tyr Val Ile Asp Phe Thr Leu Lys 85 Glu Ile Gln Ser Leu Glu Met Thr Glu Asn Phe Glu Thr Met Gly Gly 100 105 Lys Trp Ser Lys Ser Ser Val Val Gly Trp Pro Thr Val Arg Glu Arg 120 Met Arg Arg Ala Glu Pro Ala Ala Asp Gly Val Gly Ala Ala Ser Arg 135 140 Asp Leu Glu Lys His Gly Ala Ile Thr Ser Ser Asn Thr Ala Ala Thr 150 155 Asn Ala Ala Cys Ala Trp Leu Glu Ala Gln Glu Glu Glu Glu Val Gly 170 165 Phe Pro Val Thr Pro Gln Val Pro Leu Arg Pro Met Thr Tyr Lys Ala 185 Ala Val Asp Leu Ser His Phe Leu Lys Glu Lys Gly Gly Leu Glu Gly 195 200 205 Leu Ile His Ser Gln Arg Arg Gln Asp Ile Leu Asp Leu Trp Ile Tyr 215 220 His Thr Gln Gly Tyr Phe Pro Asp Trp Gln Asn Tyr Thr Pro Gly Pro 230 235 Gly Val Arg Tyr Pro Leu Thr Phe Gly Trp Cys Tyr Lys Leu Val Pro 245 250 Val Glu Pro Asp Lys Val Glu Glu Ala Asn Lys Gly Glu Asn Thr Ser 260 265 270 Leu Leu His Pro Val Ser Leu His Gly Met Asp Asp Pro Glu Arg Glu 280 Val Leu Glu Trp Arg Phe Asp Ser Arg Leu Ala Phe His His Val Ala 295 300 Arg Glu Leu His Pro Glu Tyr Phe Lys Asn Cys Thr Ser Gly His His 310 315 His His His His

> <210> 16 <211> 1290 <212> DNA

WO 01/54719

<213> human

atqqatccaa aaactttaqc cctttcttta ttaqcaqctq qcqtactaqc aqqttqtaqc 60 120 agccattcat caaatatggc gaatacccaa atqaaatcag acaaaatcat tattgctcac ogtggtgcta gcggttattt accagagcat acgttagaat ctaaagcact tgcgtttgca caacaggotg attatttaga gcaagattta gcaatgacta aggatggtog tttagtggtt 240 attcacgatc actttttaga tggcttgact gatgttgcga aaaaattccc acategtcat 300 cgtaaagatg gccgttacta tgtcatcgac tttaccttaa aagaaattca aagtttagaa 360 atgacagaaa actttgaaac catgggtggc aagtggtcaa aaagtagtgt ggttggatgg 420 cctactgtaa gggaaagaat gagacgagct gagccagcag cagatggggt gggagcagca 480 540 tetegagace tggaaaaaca tggagcaate acaagtagca atacagcage taccaatget gettgtgeet ggetagaage acaagaggag gaggaggtgg gttttccagt cacaceteag 600 gtacctttaa gaccaatgac ttacaaggca getgtagate ttagccactt tttaaaaagaa 660 720 aaggggggac tggaagggct aattcactcc caacqaaqac aaqatatcct tgatctgtgg atetaccaca cacaaggeta ettecetgat tggcagaact acacaccagg gccaggggte 780 840 agatatecae tgacetttgg atggtgetae aagetagtae cagttgagee agataaggta 900 gaagaggcca ataaaggaga gaacaccage ttgttacacc ctgtgagcct gcatggaatg gatgaccetg agagagaagt gttagagtgg aggtttgaca geegeetage attteateac 960 gtggcccgag agctgcatcc ggagtacttc aagaactgca ctagtgagcc agtagatcct 1020 1080 agactagage cetggaagea tecaggaagt cageetaaaa etgettgtac caattgetat 1140 tgtaaaaagt gttgctttca ttgccaagtt tgtttcataa caaaagcctt aggcatctcc tatggcagga agaagcggag acagcgacga agaccteete aaggcagtca gactcatcaa 1200 gtttctctat caaaqcaacc cacctcccaa tcccqaqqqq acccqacaqq cccqaaggaa 1260 1290 actagtggcc accatcacca tcaccattaa

<210> 17

<211> 411 <212> PRT

<213> human

<400> 17 Cys Ser Ser His Ser Ser Asn Met Ala Asn Thr Gln Met Lys Ser Asp 10 Lys Ile Ile Ile Ala His Arg Gly Ala Ser Gly Tyr Leu Pro Glu His 20 25 Thr Leu Glu Ser Lys Ala Leu Ala Phe Ala Gln Gln Ala Asp Tyr Leu 40 Glu Gln Asp Leu Ala Met Thr Lys Asp Gly Arg Leu Val Val Ile His 55 Asp His Phe Leu Asp Gly Leu Thr Asp Val Ala Lys Lys Phe Pro His 70 Arg His Arg Lys Asp Gly Arg Tyr Tyr Val Ile Asp Phe Thr Leu Lys 85 90 Glu Ile Gln Ser Leu Glu Met Thr Glu Asn Phe Glu Thr Met Gly Gly 100 105 Lys Trp Ser Lys Ser Ser Val Val Gly Trp Pro Thr Val Arg Glu Arg 120 125 Met Arg Arg Ala Glu Pro Ala Ala Asp Gly Val Gly Ala Ala Ser Arg 135 140 Asp Leu Glu Lys His Gly Ala Ile Thr Ser Ser Asn Thr Ala Ala Thr 150 155 Asn Ala Ala Cys Ala Trp Leu Glu Ala Gln Glu Glu Glu Glu Val Gly 165 170 Phe Pro Val Thr Pro Gln Val Pro Leu Arg Pro Met Thr Tyr Lys Ala 180 185 Ala Val Asp Leu Ser His Phe Leu Lys Glu Lys Gly Gly Leu Glu Gly 200 Leu Ile His Ser Gln Arg Arg Gln Asp Ile Leu Asp Leu Trp Ile Tyr 215 220 His Thr Gln Gly Tyr Phe Pro Asp Trp Gln Asn Tyr Thr Pro Gly Pro 230 235 Gly Val Arg Tyr Pro Leu Thr Phe Gly Trp Cys Tyr Lys Leu Val Pro 245 250

Val Glu Pro Asp Lys Val Glu Glu Ala Asn Lys Gly Glu Asn Thr Ser 260 265 Leu Leu His Pro Val Ser Leu His Gly Met Asp Asp Pro Glu Arg Glu 275 280 Val Leu Glu Trp Arg Phe A.p Ser Arg Leu Ala Phe His His Val Ala 295 300 290 Arg Glu Leu His Pro Glu Tyr Phe Lys Asn Cys Thr Ser Glu Pro Val 315 Asp Pro Arg Leu Glu Pro Trp Lys His Pro Gly Ser Gln Pro Lys Thr 335 325 330 Ala Cys Thr Asn Cys Tyr Cys Lys Lys Cys Cys Phe His Cys Gln Val 340 345 350 Cys Phe Ile Thr Lys Ala Leu Gly Ile Ser Tyr Gly Arg Lys Lys Arg 360 355 Arg Gln Arg Arg Arg Pro Pro Gln Gly Ser Gln Thr His Gln Val Ser 375 380 Leu Ser Lys Gln Pro Thr Ser Gln Ser Arg Gly Asp Pro Thr Gly Pro 390 395 Lys Glu Thr Ser Gly His His His His His His 405

<210> 18

<211> 981 <212> DNA

<213> human

<400> 18

atggatccaa gcagccattc atcaaatatg gcgaataccc aaatgaaatc agacaaaatc attattgete accettgetge tagegettat ttaccagage atacettaga atctaaagea cttgcgtttg cacaacaggc tgattattta gagcaagatt tagcaatgac taaggatggt cgtttagtgg ttattcacga tcacttttta gatggcttga ctgatgttgc gaaaaaattc ccacatcgtc atcgtaaaga tggccgttac tatgtcatcg actttacctt aaaagaaatt caaagtttag aaatgacaga aaactttgaa accatgggtg gcaagtggtc aaaaagtagt gtggttggat ggcctactgt aagggaaaga atgagacgag ctgagccagc agcagatggg gtgggagcag catctcgaga cctggaaaaa catggagcaa tcacaagtag caatacagca gctaccaatg ctgcttgtgc ctggctagaa gcacaagagg aggaggaggt gggttttcca gtcacacctc aggtaccttt aagaccaatg acttacaagg cagctgtaga tcttagccac tttttaaaag aaaagggggg actggaaggg ctaattcact cccaacgaag acaagatatc cttgatctgt ggatctacca cacacaaggc tacttccctg attggcagaa ctacacacca gggccagggg tcagatatcc actgacettt ggatggtgct acaagctagt accagttgag ccagataagg tagaagaggc caataaagga gagaacacca gcttgttaca ccctgtgagc ctgcatggaa tggatgaccc tgagagagaa gtgttagagt ggaggtttga cagccgccta gcatttcatc acgtggcccg agagctgcat ccggagtact tcaagaactg cactagtggc caccatcacc atcaccatta a

120

180

240

420

480 540

600

660 720

780

840

900

981

<210> 19 <211> 326

<212> PRT

<213> human

4400> 19
Met Aap Pro Ser Ser His Ser Ser Asn Met Ala Asn Thr Gln Met Lys
1
10
15
10
15
16
17
18
19
19
20
21
25
20
21
21
21
22
23
35
45
Tyr Leu Glu Gln Asp Leu Ala Met Thr Lys Asp Gly Arg Leu Val Ala Asp 45
35
19
45
Tyr Leu Glu Gln Asp Leu Ala Met Thr Lys Asp Gly Arg Leu Val Val Val 50
10
11
11
11
11
11
11
11
11
12
13
14
15
16
17
18
19
19
19
11
12
13
14
15
16
17
18
19
19
19
19
19
19
10
11
12
13
14
15
16
16
17
18
19
19
19
19
19
19
19
19
19
19
10
10
11
11
12
13
14
15
16
16
17
18
19
19
19
19
19
19
19
19

```
105
Gly Gly Lys Trp Ser Lys Ser Ser Val Val Gly Trp Pro Thr Val Arg
                           120
Glu Arg Met Arg Arg Ala Glu Pro Ala Ala Asp Gly Val Gly Ala Ala
                       135
                                            140
Ser Arg Asp Leu Glu Lys His Gly Ala Ile Thr Ser Ser Asn Thr Ala
                                        155
Ala Thr Asn Ala Ala Cys Ala Trp Leu Glu Ala Gln Glu Glu Glu Glu
               165
                                   170
Val Gly Phe Pro Val Thr Pro Gln Val Pro Leu Arg Pro Met Thr Tyr
                               185
Lys Ala Ala Val Asp Leu Ser His Phe Leu Lys Glu Lys Gly Gly Leu
       195
                           200
                                               205
Glu Gly Leu Ile His Ser Gln Arg Arg Gln Asp Ile Leu Asp Leu Trp
                       215
                                            220
Ile Tyr His Thr Gln Gly Tyr Phe Pro Asp Trp Gln Asn Tyr Thr Pro
                  230
                                      235
Gly Pro Gly Val Arg Tyr Pro Leu Thr Phe Gly Trp Cys Tyr Lys Leu
                                   250
Val Pro Val Glu Pro Asp Lys Val Glu Glu Ala Asn Lys Gly Glu Asn
           260
                                265
                                                   270
Thr Ser Leu Leu His Pro Val Ser Leu His Gly Met Asp Asp Pro Glu
                           280
Arg Glu Val Leu Glu Trp Arg Phe Asp Ser Arg Leu Ala Phe His His
                       295
                                           300
Val Ala Arg Glu Leu His Pro Glu Tyr Phe Lys Asn Cys Thr Ser Gly
                   310
His His His His His
               325
     <210> 20
     <211> 1242
     <212> DNA
     <213> human
     <400> 20
atggatccaa gcagccattc atcaaatatg gcgaataccc aaatgaaatc agacaaaatc
                                                                       60
attattgctc accettgctgc tagcggttat ttaccagagc atacgttaga atctaaagca
                                                                      120
                                                                      180
cttgcgtttg cacaacaggc tgattattta gagcaagatt tagcaatgac taaggatggt
cgtttagtgg ttattcacga tcacttttta gatggcttga ctgatgttgc gaaaaaattc
                                                                      240
ccacatogtc atogtaaaga tggccgttac tatgtcatog actttacctt aaaagaaatt
                                                                      300
caaagtttag aaatgacaga aaactttgaa accatgggtg gcaagtggtc aaaaagtagt
                                                                      360
gtggttggat ggcctactgt aagggaaaga atgagacgag ctgagccagc agcagatggg
                                                                      420
gtgggagcag catotogaga ootggaaaaa catggagcaa tcacaagtag caatacagca
                                                                      480
gctaccaatg ctgcttgtgc ctggctagaa gcacaagagg aggaggaggt gggttttcca
                                                                      540
gtcacacctc aggtaccttt aagaccaatg acttacaagg cagetgtaga tettagccac
                                                                      600
tttttaaaag aaaagggggg actggaaggg ctaattcact cccaacgaag acaagatatc
                                                                      660
CttgatCtgt ggatCtacca cacacaaggc tacttccctg attggcagaa ctacacaacca
gggccagggg tcagatatcc actgaccttt ggatggtgct acaagctagt accagttgag
ccagataagg tagaagaggc caataaagga gagaacacca gettgttaca ecetgtgagc
                                                                      840
ctgcatggaa tggatgaccc tgagagagaa gtgttagagt ggaggtttga cagccgccta
                                                                      900
gcattteate aegtggeeeg agagetgeat eeggagtaet teaagaaetg cactagtgag
                                                                      960
ccagtagate ctagactaga gecetggaag catecaggaa gtcagectaa aactgettgt
                                                                     1020
accaattgct attqtaaaaa qtqttqcttt cattqccaaq tttqtttcat aacaaaaqcc
                                                                     1080
ttaggcatct cctatggcag gaagaagcqq aqacaqcqac qaaqacctcc tcaaqqcagt
                                                                     1140
cagacteate aagtttetet ateaaageaa cccacetece aateeegagg ggaceegaca
                                                                     1200
```

<210> 21 <211> 413 <212> PRT <213> human

ggcccgaagg aaactagtgg ccaccatcac catcaccatt aa

<400> 21

Met Asp Pro Ser Ser His Ser Ser Asn Met Ala Asn Thr Gln Met Lys Ser Asp Lys Ile Ile Ile Ala His Arg Gly Ala Ser Gly Tyr Leu Pro 20 25 Glu His Thr Leu Glu Ser Lys Ala Leu Ala Phe Ala Gln Gln Ala Asp 40 Tyr Leu Glu Gln Asp Leu Ala Met Thr Lys Asp Gly Arg Leu Val Val 55 60 Ile His Asp His Phe Leu Asp Gly Leu Thr Asp Val Ala Lys Lys Phe 75 Pro His Arg His Arg Lys Asp Gly Arg Tyr Tyr Val Ile Asp Phe Thr 90 Leu Lys Glu Ile Gln Ser Leu Glu Met Thr Glu Asn Phe Glu Thr Met 105 Gly Gly Lys Trp Ser Lys Ser Ser Val Val Gly Trp Pro Thr Val Arg 120 125 115 Glu Arg Met Arg Arg Ala Glu Pro Ala Ala Asp Gly Val Gly Ala Ala 140 135 Ser Arg Asp Leu Glu Lys His Gly Ala Ile Thr Ser Ser Asn Thr Ala 150 155 Ala Thr Asn Ala Ala Cys Ala Trp Leu Glu Ala Gln Glu Glu Glu Glu 165 170 Val Gly Phe Pro Val Thr Pro Gln Val Pro Leu Arg Pro Met Thr Tyr 190 185 180 Lys Ala Ala Val Asp Leu Ser His Phe Leu Lys Glu Lys Gly Gly Leu 200 Glu Gly Leu Ile His Ser Gln Arg Arg Gln Asp Ile Leu Asp Leu Trp 215 220 Ile Tyr His Thr Gln Gly Tyr Phe Pro Asp Trp Gln Asn Tyr Thr Pro 230 235 Gly Pro Gly Val Arg Tyr Pro Leu Thr Phe Gly Trp Cys Tyr Lys Leu 245 250 245 Val Pro Val Glu Pro Asp Lys Val Glu Glu Ala Asn Lys Gly Glu Asn 265 Thr Ser Leu Leu His Pro Val Ser Leu His Gly Met Asp Asp Pro Glu 285 280 Arg Glu Val Leu Glu Trp Arg Phe Asp Ser Arg Leu Ala Phe His His 295 300 Val Ala Arg Glu Leu His Pro Glu Tyr Phe Lys Asn Cys Thr Ser Glu 315 310 Pro Val Asp Pro Arg Leu Glu Pro Trp Lys His Pro Gly Ser Gln Pro 330 325 Lys Thr Ala Cys Thr Asn Cys Tyr Cys Lys Lys Cys Cys Phe His Cys 340 345 Gln Val Cys Phe Ile Thr Lys Ala Leu Gly Ile Ser Tyr Gly Arg Lys 360 365 355 Lys Arg Arg Gln Arg Arg Pro Pro Gln Gly Ser Gln Thr His Gln 380 375 Val Ser Leu Ser Lys Gln Pro Thr Ser Gln Ser Arg Gly Asp Pro Thr 390 395 Gly Pro Lys Glu Thr Ser Gly His His His His His His 405

<210> 22

<211> 288 <212> DNA

<213> human

<400> 22

atggagccag tagatoctag actagagcce tggaagcate caggaagtca goctaaaact gottgtacca attgctattg taaaaagtgt tgcttcatt gccaagttg ttcataaca gottgccttag gcatctccta tggacagaga aagcgagaac aggacagag actoctccaa ggcagtcaga ctcatcaagt ttctctatca aagcaacca cotoccaatc caaagggggg cogacaggcc ogaaggaaca teagtggcaca catcaccatc accatc

9

```
<210> 23
      <211> 95
      <212> PRT
      <213> human
      <400> 23
Met Glu Pro Val Asp Pro Arg Leu Glu Pro Trp Lys His Pro Gly Ser
Gln Pro Lys Thr Ala Cys Thr Asn Cys Tyr Cys Lys Lys Cys Cys Phe
His Cys Gln Val Cys Phe Ile Thr Ala Ala Leu Gly Ile Ser Tyr Gly
       35
Arg Lys Lys Arg Arg Gln Arg Arg Pro Pro Gln Gly Ser Gln Thr
                        55
His Gln Val Ser Leu Ser Lys Gln Pro Thr Ser Gln Ser Lys Gly Glu
                    70
                                        75
Pro Thr Gly Pro Lys Glu Thr Ser Gly His His His His His His
      <210> 24
      <211> 909
      <212> DNA
      <213> human
      <400> 24
atgggtggca agtggtcaaa aagtagtgtg gttggatggc ctactgtaag ggaaagaatg
agacgagctg agccagcagc agatggggtg ggagcagcat ctcgagacct ggaaaaacat
ggagcaatca caagtagcaa tacagcagct accaatgctg cttgtgcctg gctagaagca
                                                                      180
caagaggagg aggaggtggg ttttccagtc acacctcagg tacctttaag accaatgact
                                                                      240
tacaaggcag ctgtagatct tagccacttt ttaaaagaaa aggggggact ggaagggcta
                                                                      300
atteactece aacgaagaca agatateett gatetgtgga tetaccacac acaaggetac
                                                                      360
                                                                      420
ttccctgatt ggcagaacta cacaccaggg ccaggggtca gatatccact gacctttgga
tggtgctaca agctagtacc agttgagcca gataaggtag aagaggccaa taaaggagag
                                                                      480
aacaccaget tgttacacce tgtgageetg catggaatgg atgaccetga gagagaagtg
ttagagtgga ggtttgacag cogcctagca tttcatcacg tggcccgaga gctgcatccg
                                                                      600
                                                                      660
gagtacttca agaactgcac tagtgagcca gtagatccta gactagagcc ctggaagcat
ccaggaagte agectaaaac tgettgtace aattgetatt gtaaaaagtg ttgettteat
                                                                      720
tgccaagttt gtttcataac agetgeetta ggeateteet atggcaggaa gaageggaga
                                                                      780
                                                                      840
cagogacgaa gacctectca aggcagtcag acteateaag titetetate aaagcaacce
acctcccaat ccaaagggga gccgacaggc ccgaaggaaa ctagtggcca ccatcaccat
                                                                      900
caccattaa
      <210> 25
      <211> 302
      <212> PRT
      <213> human
      <400> 25
Met Gly Gly Lys Trp Ser Lys Ser Ser Val Val Gly Trp Pro Thr Val
Arg Glu Arg Met Arg Arg Ala Glu Pro Ala Ala Asp Gly Val Gly Ala
            20
                                25
Ala Ser Arg Asp Leu Glu Lys His Gly Ala Ile Thr Ser Ser Asn Thr
                            40
                                                45
Ala Ala Thr Asn Ala Ala Cys Ala Trp Leu Glu Ala Gln Glu Glu Glu
Glu Val Gly Phe Pro Val Thr Pro Gln Val Pro Leu Arg Pro Met Thr
                                        75
Tyr Lys Ala Ala Val Asp Leu Ser His Phe Leu Lys Glu Lys Gly Gly
                85
                                   90
Leu Glu Gly Leu Ile His Ser Gln Arg Arg Gln Asp Ile Leu Asp Leu
                                105
```

Trp Ile Tyr His Thr Gln Gly Tyr Phe Pro Asp Trp Gln Asn Tyr Thr

```
120
                                               125
       115
Pro Gly Pro Gly Val Arg T/r Pro Leu Thr Phe Gly Trp Cys Tyr Lys
                       135
                                          140
Leu Val Pro Val Glu Pro Asp Lys Val Glu Glu Ala Asn Lys Gly Glu
145
                  150
                                      155
Asn Thr Ser Leu Leu His Pro Val Ser Leu His Gly Met Asp Asp Pro
               165
                                  170
                                                      175
Glu Arg Glu Val Leu Glu Trp Arg Phe Asp Ser Arg Leu Ala Phe His
           180
                              185
                                                  190
His Val Ala Arg Glu Leu His Pro Glu Tyr Phe Lys Asn Cys Thr Ser
                           200
                                               205
Glu Pro Val Asp Pro Arg Leu Glu Pro Trp Lys His Pro Gly Ser Gln
                                          220
                       215
Pro Lys Thr Ala Cys Thr Asn Cys Tyr Cys Lys Lys Cys Cys Phe His
                   230
                                      235
Cys Gln Val Cys Phe Ile Thr Ala Ala Leu Gly Ile Ser Tyr Gly Arg
               245
                                  250
                                                      255
Lys Lys Arg Arg Gln Arg Arg Pro Pro Gln Gly Ser Gln Thr His
           260
                              265
                                                  270
Gln Val Ser Leu Ser Lys Gln Pro Thr Ser Gln Ser Lys Gly Glu Pro
                      280
                                             285
Thr Gly Pro Lys Glu Thr Ser Gly His His His His His His
                       295
     <210> 26
      <211> 57
      <212> DNA
      <213> human
     <400> 26
ttcgaaacca tggccgcgga ctagtggcca ccatcaccat caccattaac ggaattc
      <210> 27
      <211> 9
      <212> PRT
      <213> human
     <400> 27
Thr Ser Gly His His His His His His
      <210> 28
      <211> 58
      <212> DNA
      <213> human
      <400> 28
ttogaaacca tggccgcgga ctagtggcca ccatcaccat caccattaac gcgaattc
      <210> 29
      <211> 9
      <212> PRT
      <213> human
      <400> 29
Thr Ser Gly His His His His His His
      <210> 30
      <211> 819
      <212> DNA
      <213> human
      <400> 30
```

atgggtggag	ctatttccat	gaggcggtcc	aggccgtctg	gagatctgcg	acagagactc	
ttgcgggcgc	gtggggagac	ttatgggaga	ctcttaggag	aggtggaaga	tggatactcg	
caatccccag	gaggattaga	caagggcttg	agctcactct	cttgtgaggg	acagaaatac	
aatcagggac	agtatatgaa	tactccatgg	agaaacccag	ctgaagagag	agaaaaatta	
gcatacagaa	aacaaaatat	ggatgatata	gatgaggaag	atgatgactt	ggtaggggta	
tcagtgaggc	caaaagttcc	cctaagaaca	atgagttaca	aattggcaat	agacatgtct	
cattttataa	aagaaaaggg	gggactggaa	gggatttatt	acagtgcaag	aagacataga	
atcttagaca	tatacttaga	aaaggaagaa	ggcatcatac	cagattggca	ggattacacc	
tcaggaccag	gaattagata	cccaaagaca	tttggctggc	tatggaaatt	agtccctgta	
aatgtatcag	atgaggcaca	ggaggatgag	gagcattatt	taatgcatcc	agctcaaact	
tcccagtggg	atgacccttg	gggagaggtt	ctagcatgga	agtttgatcc	aactctggcc	
tacacttatg	aggcatatgt	tagataccca	gaaqaqtttg	gaagcaagtc	aggcctgtca	
gaggaagagg	ttagaagaag	gctaaccgca	agaggccttc	ttaacatggc	tqacaagaag	
	ctagtggcca					

- <210> 31
- <211> 272 <212> PRT
- <213> human

<400> 31

Met Gly Gly Ala Ile Ser Met Arg Arg Ser Arg Pro Ser Gly Asp Leu 10 Arg Gln Arg Leu Leu Arg Ala Arg Gly Glu Thr Tyr Gly Arg Leu Leu 20 25 Gly Glu Val Glu Asp Gly Tyr Ser Gln Ser Pro Gly Gly Leu Asp Lys 40 Gly Leu Ser Ser Leu Ser Cys Glu Gly Gln Lys Tyr Asn Gln Gly Gln 55 Tyr Met Asn Thr Pro Trp Arg Asn Pro Ala Glu Glu Arg Glu Lys Leu 70 75 Ala Tyr Arg Lys Gln Asn Met Asp Asp Ile Asp Glu Glu Asp Asp Asp 85 90 Leu Val Gly Val Ser Val Arg Pro Lys Val Pro Leu Arg Thr Met Ser 100 105 Tyr Lys Leu Ala Ile Asp Met Ser His Phe Ile Lys Glu Lys Gly Gly 115 120 125 Leu Glu Gly Ile Tyr Tyr Ser Ala Arg Arg His Arg Ile Leu Asp Ile 135 140 Tyr Leu Glu Lys Glu Glu Gly Ile Ile Pro Asp Trp Gln Asp Tyr Thr 150 155 Ser Gly Pro Gly Ile Arg Tyr Pro Lys Thr Phe Gly Trp Leu Trp Lys 165 170 Leu Val Pro Val Asn Val Ser Asp Glu Ala Gln Glu Asp Glu Glu His 180 185 Tyr Leu Met His Pro Ala Gln Thr Ser Gln Trp Asp Asp Pro Trp Gly 195 200 205 Glu Val Leu Ala Trp Lys Phe Asp Pro Thr Leu Ala Tyr Thr Tyr Glu 215 220 Ala Tyr Val Arg Tyr Pro Glu Glu Phe Gly Ser Lys Ser Gly Leu Ser 230 235 240 Glu Glu Glu Val Arg Arg Leu Thr Ala Arg Gly Leu Leu Asn Met 245 250 255 Ala Asp Lys Lys Glu Thr Arg Thr Ser Gly His His His His His His